US8741910B2 - Soluble guanylate cyclase activators - Google Patents
Soluble guanylate cyclase activators Download PDFInfo
- Publication number
- US8741910B2 US8741910B2 US13/127,334 US200913127334A US8741910B2 US 8741910 B2 US8741910 B2 US 8741910B2 US 200913127334 A US200913127334 A US 200913127334A US 8741910 B2 US8741910 B2 US 8741910B2
- Authority
- US
- United States
- Prior art keywords
- pyrimidin
- amino
- dihydro
- dimethyl
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 0 *.CC.[2*]CC.[3*]C1([4*])CC(=O)NC2=C1C(N)=NC(C)=N2 Chemical compound *.CC.[2*]CC.[3*]C1([4*])CC(=O)NC2=C1C(N)=NC(C)=N2 0.000 description 65
- BEFDCLMNVWHSGT-UHFFFAOYSA-N [CH2-][CH+]C1CCCC1 Chemical compound [CH2-][CH+]C1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 4
- WDRSMLXIRHIGLM-UHFFFAOYSA-N CC1=NC(C)=C2C=CC=CN12.CC1=NN(C)C2=C1C=CS2.CC1=NN(C)C2=CC=CC=C21.CC1=NN(C)C2=CSC=C21 Chemical compound CC1=NC(C)=C2C=CC=CN12.CC1=NN(C)C2=C1C=CS2.CC1=NN(C)C2=CC=CC=C21.CC1=NN(C)C2=CSC=C21 WDRSMLXIRHIGLM-UHFFFAOYSA-N 0.000 description 3
- RINOAIDLQRSFNM-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC(F)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC(F)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N RINOAIDLQRSFNM-UHFFFAOYSA-N 0.000 description 3
- RMQPTENEQUQKPM-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)N=C2N RMQPTENEQUQKPM-UHFFFAOYSA-N 0.000 description 3
- CKCXCLWOZCHKAE-UHFFFAOYSA-N [CH2-][C+]1=CSC=C1 Chemical compound [CH2-][C+]1=CSC=C1 CKCXCLWOZCHKAE-UHFFFAOYSA-N 0.000 description 2
- XSGHLZBESSREDT-UHFFFAOYSA-N [CH2-][C+]1CC1 Chemical compound [CH2-][C+]1CC1 XSGHLZBESSREDT-UHFFFAOYSA-N 0.000 description 2
- BNSOCYVUMZHUCC-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC(Cl)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC(Cl)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N BNSOCYVUMZHUCC-UHFFFAOYSA-N 0.000 description 2
- MLQBAGZGQVHARD-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NC(CC3=C(F)C(F)=CC=C3F)=C3C=CC=CN13)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NC(CC3=C(F)C(F)=CC=C3F)=C3C=CC=CN13)\N=C/2N MLQBAGZGQVHARD-UHFFFAOYSA-N 0.000 description 2
- SFWAFLSRPHMCOY-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NN(CCC(F)(F)F)C3=CC=CC=C31)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NN(CCC(F)(F)F)C3=CC=CC=C31)\N=C/2N SFWAFLSRPHMCOY-UHFFFAOYSA-N 0.000 description 2
- JXGISTLZZAWIMG-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=C1CSC3)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=C1CSC3)\N=C/2N JXGISTLZZAWIMG-UHFFFAOYSA-N 0.000 description 2
- GTDUMDPQHXDMIF-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N GTDUMDPQHXDMIF-UHFFFAOYSA-N 0.000 description 2
- NXIBFDKAAHJUKJ-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC=CC=C31)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC=CC=C31)N=C2N NXIBFDKAAHJUKJ-UHFFFAOYSA-N 0.000 description 2
- GGUUIEVKQSQNCF-UHFFFAOYSA-N *.*.*.*.*.*.*.*.*.*.*.CC1=NC(C)=C2C=CC=CN12.CC1=NC(C)=C2C=CC=CN12.CC1=NC(C)=C2SC=CN12.CC1=NN(C)C2=C1C=CC=C2.CC1=NN(C)C2=C1C=CS2.CC1=NN(C)C2=C1C=NN2.CC1=NN(C)C2=C1CSC2.CC1=NN(C)C2=C1SC=C2.CC1=NN(C)C2=CC=CC=C21.CC1=NN(C)C2=CNN=C21.CC1=NN(C)C2=CSC=C21 Chemical compound *.*.*.*.*.*.*.*.*.*.*.CC1=NC(C)=C2C=CC=CN12.CC1=NC(C)=C2C=CC=CN12.CC1=NC(C)=C2SC=CN12.CC1=NN(C)C2=C1C=CC=C2.CC1=NN(C)C2=C1C=CS2.CC1=NN(C)C2=C1C=NN2.CC1=NN(C)C2=C1CSC2.CC1=NN(C)C2=C1SC=C2.CC1=NN(C)C2=CC=CC=C21.CC1=NN(C)C2=CNN=C21.CC1=NN(C)C2=CSC=C21 GGUUIEVKQSQNCF-UHFFFAOYSA-N 0.000 description 1
- NGRSJSMASYLVJS-UHFFFAOYSA-N C#CC1CCCC1.CON(C)C(=O)C1=C(Br)C=CC=C1.O=C(C#CC1CCCC1)C1=C(Br)C=CC=C1 Chemical compound C#CC1CCCC1.CON(C)C(=O)C1=C(Br)C=CC=C1.O=C(C#CC1CCCC1)C1=C(Br)C=CC=C1 NGRSJSMASYLVJS-UHFFFAOYSA-N 0.000 description 1
- JYVQQEWPSAITMU-JLMMQWLNSA-N C.CCOC(=O)C(C)C(=O)OCC.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C([N+](=O)[O-])C=C1.O=[N+]([O-])C1=CN=C(Cl)C=C1.[2H]CF Chemical compound C.CCOC(=O)C(C)C(=O)OCC.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C([N+](=O)[O-])C=C1.O=[N+]([O-])C1=CN=C(Cl)C=C1.[2H]CF JYVQQEWPSAITMU-JLMMQWLNSA-N 0.000 description 1
- WUJLTSZMCFCINJ-UHFFFAOYSA-K C1=CN=NC=C1.CC1=CC=C(S(=O)(=O)Cl)C=C1.CC1=CC=C(S(=O)(=O)N2N=CC=CC2C#N)C=C1.C[Si](C)(C)C#N.Cl[Al](Cl)Cl Chemical compound C1=CN=NC=C1.CC1=CC=C(S(=O)(=O)Cl)C=C1.CC1=CC=C(S(=O)(=O)N2N=CC=CC2C#N)C=C1.C[Si](C)(C)C#N.Cl[Al](Cl)Cl WUJLTSZMCFCINJ-UHFFFAOYSA-K 0.000 description 1
- WMSNJPHSNYDEEO-BBEAXDHJSA-L C1=CN=NC=C1.CC1=CC=C(S(=O)(=O)N2N=CC=CC2C#N)C=C1.Cl[Al](Cl)Cl.N#CC1=NN=CC=C1.[2H]B[U].[Cl-].[HH].[NH3+]CC1=NN=CC=C1 Chemical compound C1=CN=NC=C1.CC1=CC=C(S(=O)(=O)N2N=CC=CC2C#N)C=C1.Cl[Al](Cl)Cl.N#CC1=NN=CC=C1.[2H]B[U].[Cl-].[HH].[NH3+]CC1=NN=CC=C1 WMSNJPHSNYDEEO-BBEAXDHJSA-L 0.000 description 1
- CZAXYVPNHXTOIS-UHFFFAOYSA-N C1CCC2=NCCCN2CC1.CC1=CC=C(S(=O)(=O)N2N=CC=CC2C#N)C=C1.N#CC1=NN=CC=C1 Chemical compound C1CCC2=NCCCN2CC1.CC1=CC=C(S(=O)(=O)N2N=CC=CC2C#N)C=C1.N#CC1=NN=CC=C1 CZAXYVPNHXTOIS-UHFFFAOYSA-N 0.000 description 1
- SGONZEYRDJOJHZ-IPBVOBEMSA-N CC(C)(c1c(N2)nc(N/N=C(\CCC(F)(F)F)/c3cc(Cl)ccc3Br)nc1N)C2=O Chemical compound CC(C)(c1c(N2)nc(N/N=C(\CCC(F)(F)F)/c3cc(Cl)ccc3Br)nc1N)C2=O SGONZEYRDJOJHZ-IPBVOBEMSA-N 0.000 description 1
- AASSWQREDZHTLV-UHFFFAOYSA-N CC1(C)C(=O)NC2=C1/C(N)=N\C(C1=C3C=CC(C4=CC=CC=C4)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)=N/2.CC1(C)C(=O)NC2=C1/C(N)=N\C(C1=C3C=CC(Cl)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)=N/2.OB(O)C1=CC=CC=C1 Chemical compound CC1(C)C(=O)NC2=C1/C(N)=N\C(C1=C3C=CC(C4=CC=CC=C4)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)=N/2.CC1(C)C(=O)NC2=C1/C(N)=N\C(C1=C3C=CC(Cl)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)=N/2.OB(O)C1=CC=CC=C1 AASSWQREDZHTLV-UHFFFAOYSA-N 0.000 description 1
- ZYLPOOLHPLOUOD-VIBUNKPFSA-N CC1(C)C(=O)NC2=NC(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)=NC(N)=C21.N=C(N)N/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br Chemical compound CC1(C)C(=O)NC2=NC(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)=NC(N)=C21.N=C(N)N/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br ZYLPOOLHPLOUOD-VIBUNKPFSA-N 0.000 description 1
- FRPPPAFBPRAVRH-FPPIAYNRSA-N CC1(C)C(=O)NC2=NC(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)=NC(N)=C21.[H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N Chemical compound CC1(C)C(=O)NC2=NC(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)=NC(N)=C21.[H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N FRPPPAFBPRAVRH-FPPIAYNRSA-N 0.000 description 1
- DOYJIAYYKBCGAS-DOAAITPLSA-N CC1(C)C(=O)NC2=NC(N/N=C(\CCC(F)(F)F)C3=CC(Cl)=CC=C3Br)=NC(N)=C21.N=C(N)N/N=C(\CCC(F)(F)F)C1=CC(Cl)=CC=C1Br Chemical compound CC1(C)C(=O)NC2=NC(N/N=C(\CCC(F)(F)F)C3=CC(Cl)=CC=C3Br)=NC(N)=C21.N=C(N)N/N=C(\CCC(F)(F)F)C1=CC(Cl)=CC=C1Br DOYJIAYYKBCGAS-DOAAITPLSA-N 0.000 description 1
- OKMBEJDNOFEJKV-UHFFFAOYSA-N CC1=NC(C)=C2C=CC=CN12.CC1=NC(C)=C2C=CC=CN12.CC1=NN(C)C2=C1C=CS2.CC1=NN(C)C2=C1SC=C2.CC1=NN(C)C2=CC=CC=C21.CC1=NN(C)C2=CSC=C21 Chemical compound CC1=NC(C)=C2C=CC=CN12.CC1=NC(C)=C2C=CC=CN12.CC1=NN(C)C2=C1C=CS2.CC1=NN(C)C2=C1SC=C2.CC1=NN(C)C2=CC=CC=C21.CC1=NN(C)C2=CSC=C21 OKMBEJDNOFEJKV-UHFFFAOYSA-N 0.000 description 1
- KEBBJRHTOMKVKH-UHFFFAOYSA-N CC1=NN(C)C2=CC=CC=C21 Chemical compound CC1=NN(C)C2=CC=CC=C21 KEBBJRHTOMKVKH-UHFFFAOYSA-N 0.000 description 1
- YRYJRCRVWHEICU-UHFFFAOYSA-N CCC(C)(Br)C(=O)OC.CCC(C)C(=O)OC Chemical compound CCC(C)(Br)C(=O)OC.CCC(C)C(=O)OC YRYJRCRVWHEICU-UHFFFAOYSA-N 0.000 description 1
- DPEGIYUOVOTRHG-UHFFFAOYSA-N CCC(C)(Br)C(=O)OC.[C-]#[N+]C(C#N)C(C)(CC)C(=O)OC Chemical compound CCC(C)(Br)C(=O)OC.[C-]#[N+]C(C#N)C(C)(CC)C(=O)OC DPEGIYUOVOTRHG-UHFFFAOYSA-N 0.000 description 1
- FCDMNLCMDXUQBW-UHFFFAOYSA-N CCCCCCC(=O)C1=CC(F)=CC=C1Br.CCCCCCC(O)C1=CC(F)=CC=C1Br Chemical compound CCCCCCC(=O)C1=CC(F)=CC=C1Br.CCCCCCC(O)C1=CC(F)=CC=C1Br FCDMNLCMDXUQBW-UHFFFAOYSA-N 0.000 description 1
- ONIZBJZHOMFGJC-UHFFFAOYSA-N CCCCCCC(=O)C1=CC(F)=CC=C1Br.[H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCCCCC)C3=CC(F)=CC=C31)N=C2N Chemical compound CCCCCCC(=O)C1=CC(F)=CC=C1Br.[H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCCCCC)C3=CC(F)=CC=C31)N=C2N ONIZBJZHOMFGJC-UHFFFAOYSA-N 0.000 description 1
- FJSBUBNEAUNMMN-UHFFFAOYSA-N CCCCCCC(O)C1=CC(F)=CC=C1Br.O=CC1=CC(F)=CC=C1Br Chemical compound CCCCCCC(O)C1=CC(F)=CC=C1Br.O=CC1=CC(F)=CC=C1Br FJSBUBNEAUNMMN-UHFFFAOYSA-N 0.000 description 1
- FWDWDFBQWZVOFA-UHFFFAOYSA-N CCCCCCC(c1cc(F)ccc1Br)O Chemical compound CCCCCCC(c1cc(F)ccc1Br)O FWDWDFBQWZVOFA-UHFFFAOYSA-N 0.000 description 1
- WFRZRKSNTVWJNS-UHFFFAOYSA-O CCN=C=NCCCN(C)C.Cl.O=C(CC1=C(F)C=CC(F)=C1F)NCC1=NN=CC=C1.O=C(O)CC1=C(F)C(F)=CC=C1F.[Cl-].[NH3+]CC1=NN=CC=C1 Chemical compound CCN=C=NCCCN(C)C.Cl.O=C(CC1=C(F)C=CC(F)=C1F)NCC1=NN=CC=C1.O=C(O)CC1=C(F)C(F)=CC=C1F.[Cl-].[NH3+]CC1=NN=CC=C1 WFRZRKSNTVWJNS-UHFFFAOYSA-O 0.000 description 1
- LERXXHGEYKJQEV-UHFFFAOYSA-N CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(Cl)C=C1.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(N)C=C1 Chemical compound CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(Cl)C=C1.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(N)C=C1 LERXXHGEYKJQEV-UHFFFAOYSA-N 0.000 description 1
- SNGYELMVXQPVRK-UHFFFAOYSA-N CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(Cl)C=C1.NCC1=NC=C(Cl)C=C1 Chemical compound CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(Cl)C=C1.NCC1=NC=C(Cl)C=C1 SNGYELMVXQPVRK-UHFFFAOYSA-N 0.000 description 1
- HNJIIRJFFJKPGW-UHFFFAOYSA-N CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(F)C=C1.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(N)C=C1 Chemical compound CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(F)C=C1.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(N)C=C1 HNJIIRJFFJKPGW-UHFFFAOYSA-N 0.000 description 1
- DSUOFMRZXUFUEX-UHFFFAOYSA-N CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(F)C=C1.NCC1=NC=C(F)C=C1 Chemical compound CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(F)C=C1.NCC1=NC=C(F)C=C1 DSUOFMRZXUFUEX-UHFFFAOYSA-N 0.000 description 1
- JELMLILAVWNFHU-UHFFFAOYSA-N CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(N)C=C1.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C([N+](=O)[O-])C=C1 Chemical compound CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C(N)C=C1.CCOC(=O)C(NC(C)=O)(C(=O)OCC)C1=NC=C([N+](=O)[O-])C=C1 JELMLILAVWNFHU-UHFFFAOYSA-N 0.000 description 1
- NJJWHWQWPWAEIP-UHFFFAOYSA-N CCOC.CON(C)C(=O)C1=C(Br)C=CC=C1.Cl.O=C(Cl)C1=C(Br)C=CC=C1 Chemical compound CCOC.CON(C)C(=O)C1=C(Br)C=CC=C1.Cl.O=C(Cl)C1=C(Br)C=CC=C1 NJJWHWQWPWAEIP-UHFFFAOYSA-N 0.000 description 1
- LALRHQNTBOTJJC-UHFFFAOYSA-N COC(=O)C(=O)NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.COC(=O)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12 Chemical compound COC(=O)C(=O)NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.COC(=O)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12 LALRHQNTBOTJJC-UHFFFAOYSA-N 0.000 description 1
- RAPJWGDCIGSPDF-UHFFFAOYSA-N COC(=O)C(=O)NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 Chemical compound COC(=O)C(=O)NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 RAPJWGDCIGSPDF-UHFFFAOYSA-N 0.000 description 1
- CFBIVHXIXKDKGS-UHFFFAOYSA-N COC(=O)C1=CC(Cl)=CC=C1Br.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br Chemical compound COC(=O)C1=CC(Cl)=CC=C1Br.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br CFBIVHXIXKDKGS-UHFFFAOYSA-N 0.000 description 1
- HHPVRKUKVZJXGB-UHFFFAOYSA-N COC(=O)C1=CC(Cl)=CC=C1Br.O=C(CCC(F)(F)F)C1=CC(Cl)=CC=C1Br Chemical compound COC(=O)C1=CC(Cl)=CC=C1Br.O=C(CCC(F)(F)F)C1=CC(Cl)=CC=C1Br HHPVRKUKVZJXGB-UHFFFAOYSA-N 0.000 description 1
- BVXDACPZVCIDKN-UHFFFAOYSA-N COC(=O)C1=CC=CC=N1.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 Chemical compound COC(=O)C1=CC=CC=N1.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 BVXDACPZVCIDKN-UHFFFAOYSA-N 0.000 description 1
- CIHXKPKXAPVDFT-UHFFFAOYSA-N COC(=O)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12.N=C(N)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12 Chemical compound COC(=O)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12.N=C(N)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12 CIHXKPKXAPVDFT-UHFFFAOYSA-N 0.000 description 1
- FWKAESGXPYJZCW-UHFFFAOYSA-M C[Al](N)Cl.N#CC1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1.N=C(N)C1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1 Chemical compound C[Al](N)Cl.N#CC1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1.N=C(N)C1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1 FWKAESGXPYJZCW-UHFFFAOYSA-M 0.000 description 1
- UEVAUHIROFEIGP-UHFFFAOYSA-N Cc(c1c[s]cc11)n[n]1[IH]C Chemical compound Cc(c1c[s]cc11)n[n]1[IH]C UEVAUHIROFEIGP-UHFFFAOYSA-N 0.000 description 1
- AOSOZARHUJMBLZ-UHFFFAOYSA-N Cc(cn1)ccc1F Chemical compound Cc(cn1)ccc1F AOSOZARHUJMBLZ-UHFFFAOYSA-N 0.000 description 1
- CAZXYPGVKBMVAD-UHFFFAOYSA-N Cc1nc([IH]C)c(cc2)[n]1cc2Cl Chemical compound Cc1nc([IH]C)c(cc2)[n]1cc2Cl CAZXYPGVKBMVAD-UHFFFAOYSA-N 0.000 description 1
- QBNNBCPKCJQBSI-UHFFFAOYSA-N Cc1nc([IH]C)c2[n]1cccc2 Chemical compound Cc1nc([IH]C)c2[n]1cccc2 QBNNBCPKCJQBSI-UHFFFAOYSA-N 0.000 description 1
- AFVUBCQXDYJSQP-UHFFFAOYSA-N Cl.ClCCl.NCC1=NC=C(Cl)C=C1.NCC1=NC=C(Cl)C=C1 Chemical compound Cl.ClCCl.NCC1=NC=C(Cl)C=C1.NCC1=NC=C(Cl)C=C1 AFVUBCQXDYJSQP-UHFFFAOYSA-N 0.000 description 1
- NLUNXLZMWHGFRQ-UHFFFAOYSA-N Cl.ClCCl.NCC1=NC=C(F)C=C1.NCC1=NC=C(F)C=C1 Chemical compound Cl.ClCCl.NCC1=NC=C(F)C=C1.NCC1=NC=C(F)C=C1 NLUNXLZMWHGFRQ-UHFFFAOYSA-N 0.000 description 1
- IKAXFGODMREKDQ-UHFFFAOYSA-N Cl.NCC1=NC=C(Cl)C=C1.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC(Cl)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N Chemical compound Cl.NCC1=NC=C(Cl)C=C1.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC(Cl)=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N IKAXFGODMREKDQ-UHFFFAOYSA-N 0.000 description 1
- PLKSOEWOWISQMF-UHFFFAOYSA-N FC1=C(F)C(CC2=NC(I)=C3C=CC=NN23)=C(F)C=C1.FC1=C(F)C(CC2=NC=C3C=CC=NN32)=C(F)C=C1.O=C1CCC(=O)N1I Chemical compound FC1=C(F)C(CC2=NC(I)=C3C=CC=NN23)=C(F)C=C1.FC1=C(F)C(CC2=NC=C3C=CC=NN32)=C(F)C=C1.O=C1CCC(=O)N1I PLKSOEWOWISQMF-UHFFFAOYSA-N 0.000 description 1
- GKZMGRQKHFMNKD-UHFFFAOYSA-N FC1=C(F)C(CC2=NC=C3C=CC=NN32)=C(F)C=C1.O=C(CC1=C(F)C=CC(F)=C1F)NCC1=NN=CC=C1.O=P(Cl)(Cl)Cl Chemical compound FC1=C(F)C(CC2=NC=C3C=CC=NN32)=C(F)C=C1.O=C(CC1=C(F)C=CC(F)=C1F)NCC1=NN=CC=C1.O=P(Cl)(Cl)Cl GKZMGRQKHFMNKD-UHFFFAOYSA-N 0.000 description 1
- UTYIZUIIGIWPDZ-UHFFFAOYSA-N FC1=CC=C(F)C(CC2=NC(I)=C3C=CC=NN23)=C1F.N#CC1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1.N#C[Zn]C#N Chemical compound FC1=CC=C(F)C(CC2=NC(I)=C3C=CC=NN23)=C1F.N#CC1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1.N#C[Zn]C#N UTYIZUIIGIWPDZ-UHFFFAOYSA-N 0.000 description 1
- CEOKXBBTFVIUGR-UHFFFAOYSA-N N#CC1=NN(CCC(F)(F)F)C2=CC=CC=C21.N=C(N)C1=NN(CCC(F)(F)F)C2=CC=CC=C21 Chemical compound N#CC1=NN(CCC(F)(F)F)C2=CC=CC=C21.N=C(N)C1=NN(CCC(F)(F)F)C2=CC=CC=C21 CEOKXBBTFVIUGR-UHFFFAOYSA-N 0.000 description 1
- JEXUMTVGOUDAGY-UHFFFAOYSA-N N#CC1=NN(CCC(F)(F)F)C2=CC=CC=C21.[H]N1N=C(C#N)C2=CC=CC=C21 Chemical compound N#CC1=NN(CCC(F)(F)F)C2=CC=CC=C21.[H]N1N=C(C#N)C2=CC=CC=C21 JEXUMTVGOUDAGY-UHFFFAOYSA-N 0.000 description 1
- LZCAHUFIBFRBIV-UHFFFAOYSA-O N#CC1=NN=CC=C1.[Cl-].[HH].[NH3+]CC1=NN=CC=C1 Chemical compound N#CC1=NN=CC=C1.[Cl-].[HH].[NH3+]CC1=NN=CC=C1 LZCAHUFIBFRBIV-UHFFFAOYSA-O 0.000 description 1
- BPADWUZJLVVDEE-UHFFFAOYSA-N N=C(N)C1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC=NN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N Chemical compound N=C(N)C1=C2C=CC=NN2C(CC2=C(F)C(F)=CC=C2F)=N1.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC=NN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N BPADWUZJLVVDEE-UHFFFAOYSA-N 0.000 description 1
- MTZDBPUBSMZUTR-UHFFFAOYSA-N N=C(N)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NC(CC3=C(F)C(F)=CC=C3F)=C3C=CC=CN13)\N=C/2N Chemical compound N=C(N)C1=NC(CC2=C(F)C(F)=CC=C2F)=C2C=CC=CN12.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NC(CC3=C(F)C(F)=CC=C3F)=C3C=CC=CN13)\N=C/2N MTZDBPUBSMZUTR-UHFFFAOYSA-N 0.000 description 1
- YZMVRWQHMPDFIF-UHFFFAOYSA-N N=C(N)C1=NN(CCC(F)(F)F)C2=CC=CC=C21.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NN(CCC(F)(F)F)C3=CC=CC=C31)\N=C/2N Chemical compound N=C(N)C1=NN(CCC(F)(F)F)C2=CC=CC=C21.[H]N1C(=O)C(C)(C)C2=C1/N=C(C1=NN(CCC(F)(F)F)C3=CC=CC=C31)\N=C/2N YZMVRWQHMPDFIF-UHFFFAOYSA-N 0.000 description 1
- LRGFEQTZMXBILH-OWGUYUHOSA-N N=C(N)N/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br Chemical compound N=C(N)N/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br LRGFEQTZMXBILH-OWGUYUHOSA-N 0.000 description 1
- CPSJCYGYHBAONI-LOGYJBNUSA-N N=C(N)N/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br.[H]N1C(=O)CC(C)(C)C2=C(N)N=C(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)N=C21 Chemical compound N=C(N)N/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC(Cl)=CC=C1Br.[H]N1C(=O)CC(C)(C)C2=C(N)N=C(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)N=C21 CPSJCYGYHBAONI-LOGYJBNUSA-N 0.000 description 1
- XISHCEMNZMXWGX-MYHMWQFYSA-N N=C(N)N/N=C(\CCC(F)(F)F)C1=CC(Cl)=CC=C1Br.O=C(CCC(F)(F)F)C1=CC(Cl)=CC=C1Br Chemical compound N=C(N)N/N=C(\CCC(F)(F)F)C1=CC(Cl)=CC=C1Br.O=C(CCC(F)(F)F)C1=CC(Cl)=CC=C1Br XISHCEMNZMXWGX-MYHMWQFYSA-N 0.000 description 1
- UPQZBVYCXZOPHS-UWRQUICRSA-N NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.O/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 Chemical compound NC(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.O/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 UPQZBVYCXZOPHS-UWRQUICRSA-N 0.000 description 1
- ZFUIUKWIBYJFJM-UHFFFAOYSA-N NC(c1n[n](CCC(F)(F)F)c2c1cccc2)=N Chemical compound NC(c1n[n](CCC(F)(F)F)c2c1cccc2)=N ZFUIUKWIBYJFJM-UHFFFAOYSA-N 0.000 description 1
- LAAWVERAVBOWSM-UWRQUICRSA-N O/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 Chemical compound O/N=C(/CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1.O=C(CC1=C(F)C(F)=CC=C1F)C1=CC=CC=N1 LAAWVERAVBOWSM-UWRQUICRSA-N 0.000 description 1
- UQLZTIWJOXNXAT-PDGQHHTCSA-N O/N=C(/Cc(c(F)c(cc1)F)c1F)\c1ccccn1 Chemical compound O/N=C(/Cc(c(F)c(cc1)F)c1F)\c1ccccn1 UQLZTIWJOXNXAT-PDGQHHTCSA-N 0.000 description 1
- FQQYLHRUOPEINC-UHFFFAOYSA-N O=C(C#CC1CCCC1)C1=C(Br)C=CC=C1.O=C(CCC1CCCC1)C1=C(Br)C=CC=C1 Chemical compound O=C(C#CC1CCCC1)C1=C(Br)C=CC=C1.O=C(CCC1CCCC1)C1=C(Br)C=CC=C1 FQQYLHRUOPEINC-UHFFFAOYSA-N 0.000 description 1
- ILBZKSAWMWYTHM-UHFFFAOYSA-N O=C(CCC1CCCC1)C1=C(Br)C=CC=C1.[H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CCC3CCCC3)C3=C1C=CC=C3)\N=C/2N Chemical compound O=C(CCC1CCCC1)C1=C(Br)C=CC=C1.[H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CCC3CCCC3)C3=C1C=CC=C3)\N=C/2N ILBZKSAWMWYTHM-UHFFFAOYSA-N 0.000 description 1
- MXIBOBJLMPTQED-UHFFFAOYSA-N O=C(CCC1CCCC1)c1ccccc1Br Chemical compound O=C(CCC1CCCC1)c1ccccc1Br MXIBOBJLMPTQED-UHFFFAOYSA-N 0.000 description 1
- TVOCTWRFIGGZCY-UHFFFAOYSA-N O=C(Cc(c(F)c(cc1)F)c1F)c1ncccc1 Chemical compound O=C(Cc(c(F)c(cc1)F)c1F)c1ncccc1 TVOCTWRFIGGZCY-UHFFFAOYSA-N 0.000 description 1
- FQSSQVNKILYFCK-UHFFFAOYSA-N O=C(c(cccc1)c1Br)C#CC1CCCC1 Chemical compound O=C(c(cccc1)c1Br)C#CC1CCCC1 FQSSQVNKILYFCK-UHFFFAOYSA-N 0.000 description 1
- CJUCIKJLMFVWIS-UHFFFAOYSA-N O=Cc1cc(F)ccc1Br Chemical compound O=Cc1cc(F)ccc1Br CJUCIKJLMFVWIS-UHFFFAOYSA-N 0.000 description 1
- JCMGFTAUNFINAF-UHFFFAOYSA-N [C-]#[N+]C(C#N)C(C)(C)C(=O)OC Chemical compound [C-]#[N+]C(C#N)C(C)(C)C(=O)OC JCMGFTAUNFINAF-UHFFFAOYSA-N 0.000 description 1
- QBABUUHMCISUAE-UHFFFAOYSA-N [C-]#[N+]C(C#N)C(C)(C)CC(=O)OCC Chemical compound [C-]#[N+]C(C#N)C(C)(C)CC(=O)OCC QBABUUHMCISUAE-UHFFFAOYSA-N 0.000 description 1
- DHGVVFPGGYXYDK-UHFFFAOYSA-N [C-]#[N+]C(C#N)C(C)(CC)C(=O)OC Chemical compound [C-]#[N+]C(C#N)C(C)(CC)C(=O)OC DHGVVFPGGYXYDK-UHFFFAOYSA-N 0.000 description 1
- RHEONNLRDNPHSU-UHFFFAOYSA-N [C-]#[N+]C(C#N)C(C)(CCC)C(=O)OC Chemical compound [C-]#[N+]C(C#N)C(C)(CCC)C(=O)OC RHEONNLRDNPHSU-UHFFFAOYSA-N 0.000 description 1
- JPFZNXPKERZGQE-UHFFFAOYSA-N [CH2-][C+]1=C(C)NN=C1C Chemical compound [CH2-][C+]1=C(C)NN=C1C JPFZNXPKERZGQE-UHFFFAOYSA-N 0.000 description 1
- OGYBTPBTMJKGCP-UHFFFAOYSA-N [CH2-][C+]1=CC(C(F)(F)F)=CN=C1 Chemical compound [CH2-][C+]1=CC(C(F)(F)F)=CN=C1 OGYBTPBTMJKGCP-UHFFFAOYSA-N 0.000 description 1
- UCHREIPJJJOPBI-UHFFFAOYSA-N [CH2-][C+]1=CC(F)=CN=C1 Chemical compound [CH2-][C+]1=CC(F)=CN=C1 UCHREIPJJJOPBI-UHFFFAOYSA-N 0.000 description 1
- UNAHEUFWMDQXKJ-UHFFFAOYSA-N [CH2-][C+]1=CC=C(F)N=C1 Chemical compound [CH2-][C+]1=CC=C(F)N=C1 UNAHEUFWMDQXKJ-UHFFFAOYSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2-][C+]1=CC=NC=C1 Chemical compound [CH2-][C+]1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- GUDAWXFNSIJOKG-UHFFFAOYSA-N [CH2-][C+]1=CN(C)N=C1 Chemical compound [CH2-][C+]1=CN(C)N=C1 GUDAWXFNSIJOKG-UHFFFAOYSA-N 0.000 description 1
- MMUQYXAWSLMYLQ-UHFFFAOYSA-N [CH2-][C+]1=CN=CC=C1 Chemical compound [CH2-][C+]1=CN=CC=C1 MMUQYXAWSLMYLQ-UHFFFAOYSA-N 0.000 description 1
- OXQXFFYBFLCPPL-UHFFFAOYSA-N [CH2-][C+]1=CN=CN=C1 Chemical compound [CH2-][C+]1=CN=CN=C1 OXQXFFYBFLCPPL-UHFFFAOYSA-N 0.000 description 1
- CZMQCIPVQNGTJO-UHFFFAOYSA-N [CH2-][C+]1=COC=C1 Chemical compound [CH2-][C+]1=COC=C1 CZMQCIPVQNGTJO-UHFFFAOYSA-N 0.000 description 1
- FEVBOFDKPCVVMB-UHFFFAOYSA-N [CH2-][C+]1=CSC=C1C Chemical compound [CH2-][C+]1=CSC=C1C FEVBOFDKPCVVMB-UHFFFAOYSA-N 0.000 description 1
- ORNUPNRNNSVZTC-UHFFFAOYSA-N [CH2-][CH+]C1=CC=CS1 Chemical compound [CH2-][CH+]C1=CC=CS1 ORNUPNRNNSVZTC-UHFFFAOYSA-N 0.000 description 1
- YIWFBNMYFYINAD-UHFFFAOYSA-N [CH2-][CH+]C1CC1 Chemical compound [CH2-][CH+]C1CC1 YIWFBNMYFYINAD-UHFFFAOYSA-N 0.000 description 1
- ZLJFGARUWCRSOM-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC=NN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3C=CC=NN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N ZLJFGARUWCRSOM-UHFFFAOYSA-N 0.000 description 1
- CZKWQJXJHILCNX-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3SC=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(C1=C3SC=CN3C(CC3=C(F)C(F)=CC=C3F)=N1)\N=C/2N CZKWQJXJHILCNX-UHFFFAOYSA-N 0.000 description 1
- ZYEWJMDSJLNNPA-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(CCC1=C(F)C(F)=CC=C1C)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(CCC1=C(F)C(F)=CC=C1C)\N=C/2N ZYEWJMDSJLNNPA-UHFFFAOYSA-N 0.000 description 1
- JHIBXTRFACUYLZ-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(C4=CC=NC=C4)=CC=C31)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(C4=CC=NC=C4)=CC=C31)\N=C/2N JHIBXTRFACUYLZ-UHFFFAOYSA-N 0.000 description 1
- VMZULFAWLYUBHF-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CSC=C31)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CSC=C31)\N=C/2N VMZULFAWLYUBHF-UHFFFAOYSA-N 0.000 description 1
- WCIPUCQTDRHQQN-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CCC3CCCC3)C3=C1C=CC=C3)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CCC3CCCC3)C3=C1C=CC=C3)\N=C/2N WCIPUCQTDRHQQN-UHFFFAOYSA-N 0.000 description 1
- MDMPNGIEAMTYPN-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CCCC(F)(F)F)C3=CSC=C31)\N=C/2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1/N=C(N1N=C(CCCC(F)(F)F)C3=CSC=C31)\N=C/2N MDMPNGIEAMTYPN-UHFFFAOYSA-N 0.000 description 1
- YAQJSQANPDWHCJ-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1N=C(CCCC(F)(F)C(F)(F)F)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(CCCC(F)(F)C(F)(F)F)N=C2N YAQJSQANPDWHCJ-UHFFFAOYSA-N 0.000 description 1
- KDNKVLVOXDXWTC-NDOVMPOASA-N [H]N1C(=O)C(C)(C)C2=C1N=C(N/N=C(\CCC(F)(F)F)C1=CC(Cl)=CC=C1Br)N=C2N.[H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(N/N=C(\CCC(F)(F)F)C1=CC(Cl)=CC=C1Br)N=C2N.[H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)N=C2N KDNKVLVOXDXWTC-NDOVMPOASA-N 0.000 description 1
- YKQOLYRKSULSEH-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Br)=CC=C31)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Br)=CC=C31)N=C2N YKQOLYRKSULSEH-UHFFFAOYSA-N 0.000 description 1
- VRNJNDYQJZFTEU-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCC(F)(F)F)C3=CC=CC=C31)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCC(F)(F)F)C3=CC=CC=C31)N=C2N VRNJNDYQJZFTEU-UHFFFAOYSA-N 0.000 description 1
- MOTRCDYYCSJZHI-UHFFFAOYSA-N [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCCCCC)C3=CC(F)=CC=C31)N=C2N Chemical compound [H]N1C(=O)C(C)(C)C2=C1N=C(N1N=C(CCCCCC)C3=CC(F)=CC=C31)N=C2N MOTRCDYYCSJZHI-UHFFFAOYSA-N 0.000 description 1
- YIJBYWVYURNZDA-UHFFFAOYSA-N [H]N1C(=O)C(C)(CC)C2=C1/N=C(C1=C3C=CC=CN3C(CC3=CC=CC=C3F)=N1)\N=C/2N Chemical compound [H]N1C(=O)C(C)(CC)C2=C1/N=C(C1=C3C=CC=CN3C(CC3=CC=CC=C3F)=N1)\N=C/2N YIJBYWVYURNZDA-UHFFFAOYSA-N 0.000 description 1
- HDMLSSUQOBFRAY-UHFFFAOYSA-N [H]N1C(=O)C(C)(CC)C2=C1/N=C(N1N=C(CCC(C)(C)C)C3=CC(Cl)=CC=C31)\N=C/2N Chemical compound [H]N1C(=O)C(C)(CC)C2=C1/N=C(N1N=C(CCC(C)(C)C)C3=CC(Cl)=CC=C31)\N=C/2N HDMLSSUQOBFRAY-UHFFFAOYSA-N 0.000 description 1
- WTVIUXVKBSATIC-UHFFFAOYSA-N [H]N1C(=O)C(C)(CC)C2=C1/N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)\N=C/2N Chemical compound [H]N1C(=O)C(C)(CC)C2=C1/N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)\N=C/2N WTVIUXVKBSATIC-UHFFFAOYSA-N 0.000 description 1
- UFQOTFRVYYIROR-UHFFFAOYSA-N [H]N1C(=O)C(C)(CCC)C2=C1/N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)\N=C/2N Chemical compound [H]N1C(=O)C(C)(CCC)C2=C1/N=C(N1N=C(CCC(F)(F)F)C3=CC(Cl)=CC=C31)\N=C/2N UFQOTFRVYYIROR-UHFFFAOYSA-N 0.000 description 1
- PFPPWVNFISJBFG-IDEMOEMUSA-N [H]N1C(=O)CC(C)(C)C2=C(N)N=C(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)N=C21.[H]N1C(=O)CC(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N Chemical compound [H]N1C(=O)CC(C)(C)C2=C(N)N=C(N/N=C(/CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C3Br)N=C21.[H]N1C(=O)CC(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N PFPPWVNFISJBFG-IDEMOEMUSA-N 0.000 description 1
- LVVSXWMDGXAWAB-UHFFFAOYSA-N [H]N1C(=O)CC(C)(C)C2=C1N=C(CCC1=C(F)C(F)=CC=C1F)N=C2N Chemical compound [H]N1C(=O)CC(C)(C)C2=C1N=C(CCC1=C(F)C(F)=CC=C1F)N=C2N LVVSXWMDGXAWAB-UHFFFAOYSA-N 0.000 description 1
- KOADFYZDPBYHMS-UHFFFAOYSA-N [H]N1C(=O)CC(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N Chemical compound [H]N1C(=O)CC(C)(C)C2=C1N=C(N1N=C(CC3=C(F)C(F)=CC=C3F)C3=CC(Cl)=CC=C31)N=C2N KOADFYZDPBYHMS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- Cyclic GMP is an important intracellular messenger which triggers a multitude of different effects via the modulation of cGMP-dependent protein kinases, phosphodiesterases and ion channels. Examples are the relaxation of smooth muscles, the inhibition of thrombocyte activation and the inhibition of the proliferation of smooth-muscle cells and of leukocyte adhesion.
- cGMP is produced by particulate and soluble guanylate cyclases as a response to a number of extracellular and intracellular stimuli. In the case of the particulate guanylate cyclases, stimulation is essentially effected by peptidic messengers, such as the atrial natriuretic peptide or the cerebral natriuretic peptide.
- sGC soluble guanylate cyclases
- sGC soluble guanylate cyclases
- the most important stimulant is nitrogen monoxide (“NO”) or a closely related species.
- NO nitrogen monoxide
- the function of other factors such as carbon monoxide or the hydroxyl radical is still largely unclear.
- the binding of NO to the heme with formation of a penta-coordinate heme-nitrosyl complex is proposed as the mechanism of the activation by NO.
- the associated release of the histidine which is bound in the basal state to the iron converts the enzyme into the active conformation.
- Active soluble guanylate cyclases are composed of an ⁇ and a ⁇ subunit each.
- Several subunit subtypes have been described which differ from one another with respect to sequence, tissue-specific distribution and expression in different development stages.
- the subtypes ⁇ 1 and ⁇ 1 are mainly expressed in brain and lung, while ⁇ 2 is found in particular in liver and kidney.
- the subtype ⁇ 2 was shown to be present in human fetal brain.
- the subunits referred to as ⁇ 3 and ⁇ 3 were isolated from human brain and are homologous to ⁇ 1 and ⁇ 1 .
- More recent works indicate an ⁇ 2i subunit which contains an insert in the catalytic domain. All subunits show great homologies in the region of the catalytic domain.
- the enzymes presumably contain one heme per heterodimer, which is bound via ⁇ 1 -Cys-78 and/or ⁇ 1 -His-105 and is part of the regulatory center.
- guanylate-cyclase-activating factors can be reduced, or their degradation may be promoted owing to the increased occurrence of free radicals.
- the resulting reduced activation of the sGC leads, via a weakening of the respective cGMP-mediated cellular response, for example to an increase of the blood pressure, to platelet activation or to increased cell proliferation and cell adhesion.
- a weakening of the respective cGMP-mediated cellular response for example to an increase of the blood pressure, to platelet activation or to increased cell proliferation and cell adhesion.
- endothelial dysfunction, atherosclerosis, hypertension, stable or unstable angina pectoris, thromboses, myocardial infarction, strokes or erectile dysfunction results.
- Pharmacological stimulation of sGC offers a possibility to normalize cGMP production and therefore makes possible the treatment and/or prevention of such disorders.
- the compounds of the present invention effect a strong activation of guanylate cyclase and are therefore suitable for the therapy and prophylaxis of disorders which are associated with a low cGMP level.
- the present invention relates to compounds which activate soluble guanylate cyclase which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example for cardiovascular diseases such as hypertension, heart failure, pulmonary hypertension, angina pectoris, diabetes, cardiac insufficiency, thromboses or atherosclerosis.
- cardiovascular diseases such as hypertension, heart failure, pulmonary hypertension, angina pectoris, diabetes, cardiac insufficiency, thromboses or atherosclerosis.
- the invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I.
- the invention concerns compounds of Formula I which activate soluble guanylate cyclase:
- R a and R b are independently selected at each occurrence from the group consisting of —H and —C 1 -C 6 alkyl;
- R c is independently selected at each occurrence from the group consisting of —C 1 -C 6 alkyl, —CF 3 , and aryl;
- R 1 is independently selected at each occurrence from the group consisting of —H, halo, aryl, heteroaryl, —C 1 -C 6 alkyl, —C 3-10 cycloalkyl, —OR, —NO 2 , —CN, —CO 2 R a , —NR a R b , —S(O) p R c , thioxo, azido, —C( ⁇ O)R a , —OC(O) n R a , —OC( ⁇ O)OR a , —OC( ⁇ O)NR a R b , —SO
- the invention is directed to compounds of Formula II:
- R a is independently selected at each occurrence from the group consisting of —H and —C 1 -C 6 alkyl
- R 1 is independently selected at each occurrence from the group consisting of —H, halo, aryl, heteroaryl, —C 1 -C 6 alkyl and —C 3-10 cycloalkyl, said aryl, heteroaryl, alkyl and cycloalkyl optionally being substituted with one to three substituents selected from halo, —C 1 -C 6 alkyl, and —CF 3
- R 2 is selected from the group consisting of —C 1 -C 6 alkyl, —(CR a 2 ) r CF 3 , —(CR a 2 ) r C 3-10 cycloalkyl, —(CR a 2 ) r aryl, —(CR a 2 ) r heteroaryl, —(CR a 2 )
- X 1 , X 2 , X 3 and X 4 are independently selected from N or CH, provided that no more than one of X 1 , X 2 , X 3 and X 4 is N; and all other variables are as previously defined.
- X 1 , X 2 , X 3 and X 4 are independently selected from N or CH, provided that no more than one of X 1 , X 2 , X 3 and X 4 is N; and all other variables are as previously defined.
- R 3 is —C 1 -C 6 alkyl.
- R 4 is —C 1 -C 6 alkyl.
- R 3 and R 4 are methyl.
- the invention is directed to compounds of Formula II:
- X 4 is selected from the group consisting of CH and N;
- R a is independently selected at each occurrence from the group consisting of —H and —C 1 -C 6 alkyl;
- R 1 is independently selected at each occurrence from the group consisting of —H, halo and —C 1 -C 6 alkyl, said alkyl optionally being substituted with one to three substituents selected from halo, —C 1 -C 6 alkyl, and —CF 3 ;
- R 2 is selected from the group consisting of —C 1 -C 6 alkyl, —(CR a 2 ) r CF 3 , —(CR a 2 ) r C 3-10 cycloalkyl, and —(CR a 2 ) r aryl, said alkyl, cycloalkyl and aryl being optionally substituted with one to three substituents selected from halo, —C 1 -C 6 alkyl and —CF 3
- compounds of the invention are selected from the group consisting of
- Example IUPAC NAME 1 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 2 4-amino-5,5-dimethyl-2-[3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,7-dihydro-6H- pyrrolo[2,3-d]pyrimidin-6-one 3 4-amino-2-[5-chloro-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 4 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-ind
- a compound of the instant invention is selected from:
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
- the present invention is meant to include all suitable isotopic variations of the compounds of Formula I.
- different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H).
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Isotopically-enriched compounds within Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- alkyl is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
- the term “cycloalkyl” means carbocycles containing no heteroatoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, decahydronaphthyl and the like.
- Commonly used abbreviations for alkyl groups are used throughout the specification, e.g. methyl may be represented by conventional abbreviations including “Me” or CH 3 or a symbol that is an extended bond without defined terminal group, e.g.
- C 1-6 alkyl (or “C 1 -C 6 alkyl”) for example, means linear or branched chain alkyl groups, including all isomers, having the specified number of carbon atoms.
- C 1-6 alkyl includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
- C 1-4 alkyl means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. If no number is specified, 1-10 carbon atoms are intended for linear or branched alkyl groups.
- the phrase “C 1-6 alkyl, wherein the alkyl group may be unsubstituted or substituted with 1-3 fluorine atoms” refers to alkyl groups having 0, 1, 2 or 3 fluorine atoms attached to one or more carbon atoms.
- the group “CF 3 ”, for example, is a methyl group having three fluorine atoms attached the same carbon atom.
- alkenyl unless otherwise indicated, means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched or combinations thereof. Examples of alkenyl include, but are not limited to, vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
- cycloalkenyl means carbocycles containing no heteroatoms having at least one carbon-carbon double bond.
- Aryl unless otherwise indicated, means mono- and bicyclic aromatic rings containing 6-12 carbon atoms. Examples of aryl include, but are not limited to, phenyl, naphthyl, indenyl and the like. “Aryl” also includes monocyclic rings fused to an aryl group. Examples include tetrahydronaphthyl, indanyl and the like. The preferred aryl is phenyl.
- Heteroaryl unless otherwise indicated, means a mono- or bicyclic aromatic ring or ring system having 5 to 10 atoms and containing at least one heteroatom selected from O, S and N. Examples include, but are not limited to, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, and the like.
- Heteroaryl also includes aromatic heterocyclic groups fused to heterocycles that are non-aromatic or partially aromatic, and aromatic heterocyclic groups fused to cycloalkyl rings. Additional examples of heteroaryls include, but are not limited to, indazolyl, thienopyrazolyl, imidazopyridazinyl, pyrazolopyrazolyl, pyrazolopyridinyl, imidazopyridinyl and imidazothiazolyl. Heteroaryl also includes such groups in charged form, e.g., pyridinium.
- Heterocyclyl unless otherwise indicated, means a 5- or 6-membered monocyclic saturated ring containing at least one heteroatom selected from N, S and O, in which the point of attachment may be carbon or nitrogen.
- heterocyclyl include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolidinyl, 2,3-dihydrofuro(2,3-b)pyridyl, benzoxazinyl, and the like.
- the term also includes partially unsaturated monocyclic rings that are not aromatic, such as 2- or 4-pyridones attached through the nitrogen or N-substituted-(1H, 3H)-pyrimidine-2,4-diones (N-substituted uracils).
- Heterocyclyl moreover includes such moieties in charged form, e.g., piperidinium.
- Halogen or halo
- fluorine fluoro
- chlorine chloro
- bromine bromine
- iodine iodo
- substitution by a named substituent is permitted on any atom in a ring (e.g., aryl, a heteroaryl ring, or a saturated heterocyclic ring) provided such ring substitution is chemically allowed and results in a stable compound.
- a “stable” compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
- the present invention includes all stereoisomeric forms of the compounds of the Formula I. Centers of asymmetry that are present in the compounds of Formula I can all independently of one another have S configuration or R configuration.
- the invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios.
- enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios.
- the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios.
- the preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis.
- a derivatization can be carried out before a separation of stereoisomers.
- the separation of a mixture of stereoisomers can be carried out at the stage of the compounds of the Formula I or at the stage of an intermediate during the synthesis.
- the present invention also includes all tautomeric forms of the compounds of Formula I.
- the invention also includes the corresponding physiologically or toxicologically acceptable salts, in particular the pharmaceutically utilizable salts.
- the compounds of the Formula I which contain acidic groups can be present on these groups and can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts.
- Examples of such salts are sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
- Compounds of the Formula I which contain one or more basic groups i.e.
- the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). Salts can be obtained from the compounds of the Formula I by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts.
- the present invention also includes all salts of the compounds of the Formula I which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of physiologically acceptable salts.
- the 8- or 9-membered heteroaryl is composed of a first ring which is a 5-membered ring containing two nitrogens, fused to a second ring that optionally contains one or more heteroatoms (N, O or S).
- the two nitrogens of the first ring may be fully in the first ring, or one of the two nitrogens may be shared at a fusion point with the second ring.
- the 8- or 9-membered bicyclic heteroaryl is attached to the pyrmidinyl ring and the —CH 2 —R 2 group of structural Formula I or II via the first ring, and more specifically via each of the atoms in the first ring that are adjacent to each of the two atoms shared by both rings in the bicyclic heteroaryl.
- X 1 , X 3 and X 4 are selected from CH or N, provided no more than one is N.
- X 1 and X 4 are CH.
- * indicates attachment to the pyrmidinyl ring and ** indicates attachment to the —CH 2 —R 2 of structural Formula I or II.
- R 1 is independently selected from H, halo, aryl, heteroaryl, —C 1 -C 6 alkyl, and —C 3-10 cycloalkyl, said aryl, heteroaryl, alkyl and cycloalkyl optionally being substituted with one to three substituents selected from halo, —C 1 -C 6 alkyl, —OR, oxo and —CF 3 .
- R 1 is aryl or —C 1 -C 6 alkyl, wherein said aryl or —C 1 -C 6 alkyl is optionally substituted with one to three substituents selected from halo or —CF 3 .
- R 2 is selected from —C 1 -C 6 alkyl, —(CR a 2 ) r —C 3-10 cycloalkyl, —(CR a 2 ) r aryl, —(CR a 2 ) r heteroaryl, and —(CR a 2 ) r C(O)Oalkyl, said alkyl, cycloalkyl, aryl, and heteroaryl being optionally substituted with one to three substituents selected from halo, —C 1 -C 6 alkyl, —CF 3 , —CN and —OR.
- R 2 is selected from —C 1 -C 6 alkyl and —(CR a 2 ) r aryl, said alkyl and aryl being optionally substituted with one to three substituents selected from halo, —C 1 -C 6 alkyl and —CF 3 .
- R 3 and R 4 are both alkyl, they may be joined together with the carbon to which they are commonly attached to form a 3-6 membered cycloalkyl ring.
- R 3 and R 4 are each C 1 -C 6 alkyl. In a further embodiment, R 3 and R 4 are each methyl.
- the present invention also relates to processes for the preparation of the compounds of the Formula I which are described in the following and by which the compounds of the invention are obtainable.
- the compounds of the Formula I according to the invention effect an increase of the cGMP concentration via the activation of the soluble guanylate cyclase (sGC), and they are therefore useful agents for the therapy and prophylaxis of disorders which are associated with a low or decreased cGMP level or which are caused thereby, or for whose therapy or prophylaxis an increase of the present cGMP level is desired.
- the activation of the sGC by the compounds of the Formula I can be examined, for example, in the activity assay described below.
- disorders and pathological conditions which are associated with a low cGMP level or in which an increase of the cGMP level is desired and for whose therapy and prophylaxis it is possible to use compounds of the Formula I are, for example, cardiovascular diseases, such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary hypertension, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency or pulmonary hypertonia, or, for example, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency and diabetes.
- cardiovascular diseases such as endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary hypertension, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency or pulmonary hypertonia, or, for example, erectile dysfunction, asthma bron
- the compounds of the Formula I and their physiologically acceptable salts can be administered to animals, preferably to mammals, and in particular to humans, as pharmaceuticals by themselves, in mixtures with one another or in the form of pharmaceutical preparations.
- the term “patient” includes animals, preferably mammals and especially humans, who use the instant active agents for the prevention or treatment of a medical condition. Administering of the drug to the patient includes both self-administration and administration to the patient by another person.
- the patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk of said disease or medical condition.
- a subject of the present invention therefore also are the compounds of the Formula I and their physiologically acceptable salts for use as pharmaceuticals, their use for activating soluble guanylate cyclase, for normalizing a disturbed cGMP balance and in particular their use in the therapy and prophylaxis of the abovementioned syndromes as well as their use for preparing medicaments for these purposes.
- a therapeutically effective amount is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- a prophylactically effective amount is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. It is understood that a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of hypertension, and a prophylactically effective amount, e.g., for prevention of myocardial infarction.
- a subject of the present invention are pharmaceutical preparations (or pharmaceutical compositions) which comprise as active component an effective dose of at least one compound of the Formula I and/or a physiologically acceptable salt thereof and a customary pharmaceutically acceptable carrier, i.e., one or more pharmaceutically acceptable carrier substances and/or additives.
- a subject of the invention are, for example, said compound and its physiologically acceptable salts for use as a pharmaceutical, pharmaceutical preparations which comprise as active component an effective dose of said compound and/or a physiologically acceptable salt thereof and a customary pharmaceutically acceptable carrier, and the uses of said compound and/or a physiologically acceptable salt thereof in the therapy or prophylaxis of the abovementioned syndromes as well as their use for preparing medicaments for these purposes.
- the pharmaceuticals according to the invention can be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously in the form of solutions for injection or infusion.
- Suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or the inhalative administration in the form of nasal sprays or aerosol mixtures, or, for example, microcapsules, implants or rods.
- the preferred administration form depends, for example, on the disease to be treated and on its severity.
- the amount of active compound of the Formula I and/or its physiologically acceptable salts in the pharmaceutical preparations normally is from 0.2 to 200 mg, preferably from 1 to 200 mg, per dose, but depending on the type of the pharmaceutical preparation it can also be higher.
- the pharmaceutical preparations usually comprise 0.5 to 90 percent by weight of the compounds of the Formula I and/or their physiologically acceptable salts.
- the preparation of the pharmaceutical preparations can be carried out in a manner known per se.
- one or more compounds of the Formula I and/or their physiologically acceptable salts together with one or more solid or liquid pharmaceutical carrier substances and/or additives (or auxiliary substances) and, if desired, in combination with other pharmaceutically active compounds having therapeutic or prophylactic action, are brought into a suitable administration form or dosage form which can then be used as a pharmaceutical in human or veterinary medicine.
- Carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc.
- Suitable carriers for the preparation of solutions, for example of solutions for injection, or of emulsions or syrups are, for example, water, physiologically sodium chloride solution, alcohols such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils, etc.
- Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
- the pharmaceutical preparations can also contain customary additives, for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
- customary additives for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
- the dosage of the active compound of the Formula I to be administered and/or of a physiologically acceptable salt thereof depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to compounds of the Formula I.
- a daily dose of approximately 0.01 to 100 mg/kg, preferably 0.01 to 10 mg/kg, in particular 0.3 to 5 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the desired results.
- the daily dose can be administered in a single dose or, in particular when larger amounts are administered, be divided into several, for example two, three or four individual doses. In some cases, depending on the individual response, it may be necessary to deviate upwards or downwards from the given daily dose.
- the compounds of the Formula I activate the soluble guanylate cyclase.
- They can also be employed as a scientific tool or as aid for biochemical investigations in which such an effect on guanylate cyclase is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples.
- the compounds of the Formula I and salts thereof can furthermore be employed, as already mentioned above, as intermediates for the preparation of other pharmaceutically active compounds.
- angiotensin converting enzyme inhibitors e.g, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril), angiotensin II receptor antagonists (e.g., losratan, valsartan, candesartan, olmesartan, telmesartan) neutral endopeptidase inhibitors (e.g., thiorphan and phosphoramidon), aldosterone antagonists, renin inhibitors (e.g.
- angiotensin converting enzyme inhibitors e.g, alacepril, benazepril, capto
- urea derivatives of di- and tri-peptides See U.S. Pat. No. 5,116,835), amino acids and derivatives (U.S. Pat. Nos. 5,095,119 and 5,104,869), amino acid chains linked by non-peptidic bonds (U.S. Pat. No. 5,114,937), di- and tri-peptide derivatives (U.S. Pat. No. 5,106,835), peptidyl amino diols (U.S. Pat. Nos. 5,063,208 and 4,845,079) and peptidyl beta-aminoacyl aminodiol carbamates (U.S. Pat. No. 5,089,471); also, a variety of other peptide analogs as disclosed in the following U.S.
- statone-containing peptides U.S. Pat. No. 5,066,643
- enalkrein RO 42-5892
- a 65317 A 65317
- CP 80794 ES 1005
- ES 8891 SQ 34017
- aliskiren (2(S),4(S),5(S),7(S)—N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)-phenyl]-octanamid hemifumarate) SPP600, SPP630 and SPP635)
- endothelin receptor antagonists e.g., amlodipine, nifedipine, verastrial, diltiazem, gallopamil, niludipine,
- lipid lowering agents e.g., simvastatin, lovastatin, ezetamibe, atorvastatin, pravastatin
- metabolic altering agents including insulin sensitizing agents and related compounds (e.g., muraglitazar, glipizide, metformin, rosiglitazone) or with other drugs beneficial for the prevention or the treatment of the above-mentioned diseases including nitroprusside and diazoxide.
- HPLC High pressure liquid chromatography HOAc - acetic acid
- iPA isopropyl alcohol
- iPr isopropyl
- i-PrOH isopropanol
- LDA lithium diisopropyl amide
- LCMS liquid chromatography - mass spectroscopy
- MeOH methanol min, min.
- compounds with structure 1 may be prepared by the sequence depicted in Scheme 1.
- Ring structure Z represents a five or six membered aryl or heteroaryl ring.
- Deprotonation of malononitrile 2 with a base such as sodium hydride, potassium t-butoxide or potassium carbonate in the presence of the alpha bromo ester 3 affords the compound 4.
- the reaction is typically done in a solvent such as DMF or THF.
- compound 3 may be prepared from the corresponding ester by bromination with N-bromosuccinimide in a solvent such as carbon tetrachloride.
- the reaction may also be carried out in the absence of a base.
- Compound 1 is prepared by treating compound 6 with CuI and a ligand such as trans-N,N′-dimethylcyclohexane-1,2-diamine or N,N′-dimethylethylenediamine in a solvent such as DMF or NMP at ambient temperature to 160° C.
- the reaction may also be carried out in the absence of a ligand.
- the copper mediated cyclization of hydrazones to form indazoles may also be carried out using the conditions described by Liu, R. et al Synthetic Communications 2008, 32(2), 249.
- the copper mediated cyclization shown in Scheme 1 may also be carried out on the corresponding chloride or iodide.
- Compound 5 is prepared by treatment of the ketone 9 with aminoguanidine hydrochloride and boron trifluoride etherate in an alcohol solvent such as methanol at 100° C.
- the ketone 9 may be prepared using methods familiar to those skilled in the art. Some of the methods are depicted in Scheme 3. Addition of the alkyl or aryl magnesium chloride 11 (or bromide, iodide) to the aldehyde 10 gives the benzyl alcohol 12. The compound 11, if not commercial, may be prepared from the corresponding halide using magnesium metal as described by Lai, Y. H. Synthesis 1981, 585. Ketone 9 is prepared by treating compound 12 with an oxidizing reagent such as chromium trioxide. Ketone 9 may also prepared by the addition of 11 to the amide 15.
- ketone 9 may be prepared from the acid chloride 13 and the zinc compound 14 using a palladium catalyst such as Pd(PPh 3 ) 4 as described by Zhu, L. et al Journal of Organic Chemistry 1991, 56(4), 1445.
- the ketone 9 where R 2 is CH 2 CO 2 Et may be prepared from the acid chloride 13 and (1-ethoxycyclopropoxy)trimethylsilane using a palladium catalyst such as PdCl 2 (PPh 3 ) 2 as described by Aoki, S. et al Tetrahedron Letters 1989, 30(47), 6541.
- compounds with structure 18 may be prepared by the sequence depicted in Scheme 4.
- Conversion of the nitrile 16 to the amidine 17 can be accomplished with a reagent such as amino(chloro)methylaluminum in a non-polar solvent such as toluene at 100° C. as described by Garigipati, R. S. Tetrahedron Letters 1990, 31(14), 1969.
- Reaction of amidine 17 with the malononitrile 4 as described in Scheme 1 affords 18.
- Scheme 5 outlines the preparation of nitrile intermediate 16.
- Amino methyl compound 19 can be coupled with the carboxylic acid 8 and a coupling reagent such as EDC and an organic base such as DIEA or TEA in a solvent like DCM to afford the amide 20.
- This can be converted to the imidazopyridine 21 with phosphorous oxychloride in a chlorinated solvent such DCE under refluxing conditions.
- Iodination of 21 to afford 22 can be accomplished with MS in solvents like DCM or acetonitrile at ambient temperature or under reflux conditions.
- the nitrile 16 can be prepared by treatment of the iodide 22 with zinc cyanide in the presence of a suitable catalyst such as Pd(PPh 3 ) 4 or Pd 2 (dba) 3 and ligand such as dppf in a polar solvent such as DMF.
- a suitable catalyst such as Pd(PPh 3 ) 4 or Pd 2 (dba) 3 and ligand such as dppf in a polar solvent such as DMF.
- the amino methyl compound 19D may be prepared as outlined in Scheme 6.
- Pyridazine 23 can be converted to 2-cyano pyridazine 25 using the chemistry described by Dostal, W. and Heinisch, G. Heterocycles 1986, 793.
- Reduction of the nitrile 25 can be accomplished under high pressure hydrogenation conditions using a suitable catalyst such as palladium on carbon in an alcoholic solvent such as methanol or ethanol and a suitable acid such as hydrochloric acid to afford the 2-amino methylpyridazine hydrochloride 19D.
- the amino methyl compounds 19B and 19C may be prepared as outlined in Scheme 7. Addition of diethyl acetamidomalonate to 2-chloro-5-nitropyridine affords compound 27. Reduction of 27 with hydrogen and palladium on carbon gives the amine 28. Sandmeyer reaction of 28 using the indicated conditions gives the halo (chloro or fluoro) pyridine 29. Saponification of 29 with base followed by treatment with hydrochloric acid gives amino methyl compounds 19B and 19C.
- compounds with structure 36 are prepared as outlined in Scheme 8.
- the ketone 30 may be prepared as described for compound 9 in Schemes 2 and 3. Reaction of compound 30 with hydroxylamine in an alcohol solvent affords the oxime 31. Reduction with zinc metal followed by reaction with methyl oxalyl chloride gives compound 33. Cyclization of 33 using phosphorous oxychloride to give 34 may be carried out as described in Scheme 5. Conversion of the ester 34 to the amidine 35 can be accomplished with a reagent such as amino(chloro)methylaluminum in a non-polar solvent such as toluene at 100° C. Reaction of amidine 35 with the malononitrile 4 as described in Scheme 1 affords 36.
- compounds with the structure 40 are prepared as outlined in Scheme 9. Alkylation of nitrile indazole 37 with a base such as cesium carbonate or sodium hydride and an alkyl halide in a solvent such as DMF affords the compound 38. Compound 38 can be converted to compound 40 as described in Scheme 4.
- compounds with the structure 44 are prepared as outlined in Scheme 10. Reaction of the unsaturated nitrile 41 with ethyl bromoacetate, zinc and titanium biscyclopentadienyl dichloride catalyst as described by Ding, Y. et al Tetrahedron 1997, 53(8), 249 affords the compound 42.
- Compound 44 is prepared from compound 42 using the conditions described in Scheme 1.
- compound 4 may be substituted with compound 42 in Schemes 4, 8 and 9 to afford the corresponding 6-membered ring amides.
- Compounds of the present invention may be prepared using methods familiar to those skilled in the art.
- One such method is the palladium mediated coupling of a boronic acid or ester and an aryl halide.
- An example of this method is shown in Scheme 11.
- the imidazopyridine 45 can be coupled to any suitable boronic acid or boronic ester such as phenyl boronic acid with a catalyst such as dichlorobis[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct to give 46.
- MS data were recorded on a Waters Micromass unit, interfaced with a Hewlett-Packard (Agilent 1100) HPLC instrument, and operating on MassLynx/OpenLynx software; electrospray ionization was used with positive (ES+) or negative ion (ES ⁇ ) detection; and diode array detection; the various methods used for analytical HPLC mass spectrometery conditions are listed below:
- a DMF (4 mL) solution containing malononitrile (0.484 g, 7.32 mmol) was added dropwise to a DMF (3 mL) suspension of sodium hydride (60 wt %, 0.30 g, 7.49 mmol) cooled in an ice bath. After 10 min a DMF (3 mL) solution containing the intermediate from Step A (1.099 g, 5.63 mmol) was added. The ice bath was removed and the solution stirred overnight at room temperature. The solution was partitioned between ethyl ether and aqueous 1N HCl. The organic phase was washed with aqueous 1N HCl, brine and dried over MgSO 4 . The solution was filtered and concentrated.
- Zinc powder (1.23 g, 18.85 mmol) was added to a THF (20 mL) solution of isopropylidenemalononitrile (1.0 g, 9.42 mmol), ethyl bromoacetate (3.15 g, 18.85 mmol) and titanium bis(cyclopentadienyl)dichloride (235 mg, 0.94 mmol). After stirring for 1 hour the solution was partitioned between ethyl acetate and aqueous 1N HCl. The organic phase was washed with water, brine, dried over MgSO 4 and filtered.
- THF solution of sodium bis(trimethylsilyl)amide (1.0M, 194 mL, 194 mmol) was added dropwise to a ⁇ 78° C. THF (400 mL) solution containing methyl 2-bromo-5-chlorobenzoate (16.10 g, 64.5 mmol) and 4,4,4-trifluorobutyric acid (9.17 g, 64.5 mmol). After stirring for 15 min at ⁇ 78° C. the solution was warmed to 0° C. and stirred for an additional 2 hours. The reaction was quenched with an excess of aqueous 1N HCl (ca 400 mL) and stirred overnight at room temperature. The solution was concentrated to remove the majority of the THF.
- Example 2 The compound of Example 1 (9 mg, 0.02 mmol) and palladium hydroxide on carbon (20 wt %, 15 mg) in MeOH (ca 10 mL) were stirred under a hydrogen atmosphere (balloon). After stirring for several hours the solution was filtered through celite and concentrated. The residue was purified by preparative TLC using 5% MeOH/DCM as the eluent to give the indicated compound.
- Trimethylaluminum (2.0M toluene, 10 mL, 20 mmol) was added to ammonium chloride (1.07 g, 20 mmol) suspended in toluene (30 mL) at 0° C. The solution was then stirred at room temperature for 2 hours to give a 0.5M amino(chloro)methylaluminum solution in toluene.
- Potassium t-butoxide (0.972 g, 8.66 mmol) was added to 3-cyano indazole (1.24 g, 8.66 mmol) in 8 mL THF. After 5 min 1,1,1-trifluoro-3-iodopropane (1.94 g, 8.66 mmol) was added. The solution was then heated to 60° C. After 1 hour 6 mL of DMF, potassium t-butoxide (0.972 g, 8.66 mmol) and 1,1,1-trifluoro-3-iodopropane (1.94 g, 8.66 mmol) were added. After stirring for an additional 2 hours at 60° C.
- sGC is a heme-containing enzyme that converts GTP to secondary messenger cGMP. Increases in cGMP levels affect several physiological processes including vasorelaxation through multiple downstream pathways. The rate by which sGC catalyzes cGMP formation is greatly increased by NO and by recently discovered NO-independent activators and stimulators. Heme-dependent activators (HDAs) preferentially activate sGC containing a ferrous heme group. To determine the effect of sGC activators on enzyme activity, the CASA assay was developed to monitor the generation of cGMP in a cell line that stably expresses the heterodimeric sGC protein.
- HDAs Heme-dependent activators
- a CHO-K1 cell line stably expressing the sGC ⁇ 1/ ⁇ 1 heterodimer was generated using a standard transfection protocol.
- CHO-K1 cells were transfected with plasmids pIREShyghsGC ⁇ 1 and pIRESneo-hsGC ⁇ 1 simultaneously using FUGENE reagent.
- Clones that stably express both subunits were selected with hygromycin and neomycin for ⁇ 2 weeks. Clone #7 was chosen for the assay and was designated CHO-K1/sGC.
- CHO-K1/sGC cells were maintained in F-K12 medium containing 10% heat-inactivated Fetal Bovine Serum (FBS), 100 ⁇ g/mL penicillin/streptomycin, 0.5 mg/mL hygromycin and 0.25 mg/mL G418.
- FBS Fetal Bovine Serum
- FBS heat-inactivated Fetal Bovine Serum
- cells were harvested in EBSS Assay Buffer (EAB) containing 5 mM MgCl2, 10 mM HEPES and 0.05% BSA and cell density was adjusted to 2 ⁇ 10 6 /mL with EAB.
- IBMX (3-isobutyl-1-methylxanthin, 0.5 mM) was added to inhibit degradation of cGMP.
- Compounds of the instant invention had EC 50s less than or equal to about 1 ⁇ M. Preferable compounds had an EC 50s less than or equal to about 500 nM. Results for specific compounds are as follows:
- Example IUPAC NAME EC 50 1 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,5-dimethyl- 86 nM 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 3
Abstract
Description
are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I.
is an 8- or 9-membered heteroaryl;
Ra and Rb are independently selected at each occurrence from the group consisting of —H and —C1-C6 alkyl;
Rc is independently selected at each occurrence from the group consisting of —C1-C6 alkyl, —CF3, and aryl;
R1 is independently selected at each occurrence from the group consisting of —H, halo, aryl, heteroaryl, —C1-C6 alkyl, —C3-10 cycloalkyl, —OR, —NO2, —CN, —CO2Ra, —NRaRb, —S(O)pRc, thioxo, azido, —C(═O)Ra, —OC(O)nRa, —OC(═O)ORa, —OC(═O)NRaRb, —SO2NRaNRb, —NRa(C═O)nRb, —NRaSO2Rb, —NRaC(═O)ORb, —NRaC(O)NRaRb, —NRaSO2NRaRb, —C2-10alkenyl, and —C2-10alkynyl, said aryl, heteroaryl, alkyl, cycloalkyl, alkenyl and alkynyl optionally being substituted with one to three substituents selected from halo, —C1-C6 alkyl, —OR, oxo, aryl, heteroaryl, —C3-10 cycloalkyl, —NO2, —CN, —CO2Ra, NRaRb, —S(O)pRc, thioxo, azido, —C(═O)Ra, —O(C═O)nRa, —OC(═O)ORa, —OC(═O)NRaRb, —SO2NRaNRb, —NRa(C═O)nRb, —NRaSO2Rb, —NRaC(═O)ORb, —NRaC(═O)NRaRb, —NRaSO2NRaRb and —CF3;
R2 is selected from the group consisting of —C1-C6 alkyl, —(CRa 2)rOR, —(CRa 2)rS(O)pRc, —(CRa 2)rCF3, —(CRa 2)r—C3-10cycloalkyl, —(CRa 2)raryl, —(CRa 2)rheteroaryl, —(CRa 2)r—C2-10alkenyl, —(CRa 2)r—C2-10alkyl, and —(CRa 2)rC(O)Oalkyl, said alkyl, cycloalkyl, aryl, hetetoaryl, alkenyl and alkynyl being optionally substituted with one to three substituents selected from halo, —C1-C6 alkyl, —CF3, —CN and —OR;
R is independently selected at each occurrence from the group consisting of —H, —C1-C6 alkyl, —CF3, and aryl;
R3 and R4 are independently selected from the group consisting of —H and —C1-C6 alkyl; when R3 and R4 are C1-C6 alkyl they may optionally be joined to form a cycloalkyl;
m is 0 (zero), 1, 2, or 3;
p is 0 (zero), 1 or 2;
r is 0 (zero), 1, 2, 3, 4, 5, or 6; and
z is 0 (zero) or 1.
is an 8- or 9-membered heteroaryl;
Ra is independently selected at each occurrence from the group consisting of —H and —C1-C6 alkyl;
R1 is independently selected at each occurrence from the group consisting of —H, halo, aryl, heteroaryl, —C1-C6 alkyl and —C3-10 cycloalkyl, said aryl, heteroaryl, alkyl and cycloalkyl optionally being substituted with one to three substituents selected from halo, —C1-C6 alkyl, and —CF3;
R2 is selected from the group consisting of —C1-C6 alkyl, —(CRa 2)rCF3, —(CRa 2)rC3-10cycloalkyl, —(CRa 2)raryl, —(CRa 2)rheteroaryl, —(CRa 2)ralkenyl, —(CRa 2)ralkynyl, and —(CRa 2)rC(O)Oalkyl, said alkyl, cycloalkyl, aryl, hetetoaryl, alkenyl and alkynyl being optionally substituted with one to three substituents selected from halo, —C1-C6 alkyl, —CF3, —CN, and —OR;
R is independently selected at each occurrence from the group consisting of —H, —C1-C6 alkyl and aryl;
R3 and R4 are independently selected from the group consisting of H and C1-C6 alkyl; when R3 and R4 are C1-C6 alkyl they may optionally be joined to form a cycloalkyl;
m is 0, 1, 2 or 3; and
r is 0, 1, 2, 3, 4, 5, or 6.
where * indicates attachment to the pyrmidinyl ring and ** indicates attachment to the —CH2—R2 of structural Formula I or II;
X1, X2, X3 and X4 are independently selected from N or CH, provided that no more than one of X1, X2, X3 and X4 is N; and all other variables are as previously defined.
where * indicates attachment to the pyrmidinyl ring and ** indicates attachment to the —CH2—R2 of structural Formula I or II;
X1, X2, X3 and X4 are independently selected from N or CH, provided that no more than one of X1, X2, X3 and X4 is N; and all other variables are as previously defined.
X4 is selected from the group consisting of CH and N;
Ra is independently selected at each occurrence from the group consisting of —H and —C1-C6 alkyl;
R1 is independently selected at each occurrence from the group consisting of —H, halo and —C1-C6 alkyl, said alkyl optionally being substituted with one to three substituents selected from halo, —C1-C6 alkyl, and —CF3;
R2 is selected from the group consisting of —C1-C6 alkyl, —(CRa 2)rCF3, —(CRa 2)rC3-10cycloalkyl, and —(CRa 2)raryl, said alkyl, cycloalkyl and aryl being optionally substituted with one to three substituents selected from halo, —C1-C6 alkyl and —CF3;
R is independently selected from —H, —C1-C6 alkyl and aryl;
R3 and R4 are each C1-C6 alkyl;
M is 0, 1, 2 or 3; and
r is 0, 1, 2, or 3.
Example | IUPAC NAME |
1 | 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
2 | 4-amino-5,5-dimethyl-2-[3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
3 | 4-amino-2-[5-chloro-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
4 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,7-dihydro- |
6H-pyrrolo[2,3-d]pyrimidin-6-one | |
5 | 4-amino-2-(5-fluoro-3-hexyl-1H-indazol-1-yl)-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
6 | 4-amino-2-[5-bromo-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
7 | 4-amino-5,5-dimethyl-2-[5-pyridin-4-yl-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl] |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
8 | 4-amino-5,5-dimethyl-2-[3-(4,4,4-trifluorobutyl)-1H-thieno[3,4-c]pyrazol-1-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
9 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-thieno[3,4-c]pyrazol-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
10 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-4,6-dihydro-1H-thieno[3,4- |
c]pyrazol-1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
11 | 4-amino-2-[3-(2-cyclopentylethyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
12 | 4-amino-2-[3-(2-fluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
13 | 4-amino-2-[5-chloro-3-(2-fluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro- |
6H-pyrrolo[2,3-d]pyrimidin-6-one | |
14 | 4-amino-2-[5-fluoro-3-(2-fluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro- |
6H-pyrrolo[2,3-d]pyrimidin-6-one | |
15 | 4-amino-2-[5-chloro-3-(2,3-difluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
16 | 4-amino-2-[3-(2,3-difluorobenzyl)-5-fluoro-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
17 | 4-amino-2-[3-(2,3-difluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
18 | 4-amino-2-[3-(2-fluorobenzyl)-5-phenyl-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro- |
6H-pyrrolo[2,3-d]pyrimidin-6-one | |
19 | 4-amino-2-[5-fluoro-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
20 | 4-amino-5,5-dimethyl-2-[5-pyridin-3-yl-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
21 | 4-amino-5,5-dimethyl-2-[5-(1-methyl-1H-pyrazol-4-yl)-3-(2,3,6-trifluorobenzyl)- |
1H-indazol-1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
22 | 4-amino-2-[5-(3,5-dimethyl-1H-pyrazol-4-yl)-3-(2,3,6-trifluorobenzyl)-1H-indazol- |
1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
23 | 4-amino-2-[5-(3-furyl)-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
24 | 4-amino-5,5-dimethyl-2-[5-(4-methyl-3-thienyl)-3-(2,3,6-trifluorobenzyl)-1H- |
indazol-1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
25 | 4-amino-2-[5-cyclopropyl-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
26 | 4-amino-5,5-dimethyl-2-[5-pyridin-4-yl-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
27 | 4-amino-5,5-dimethyl-2-[5-phenyl-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl)-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
28 | 4-amino-2-[5-chloro-3-(pyrimidin-5-ylmethyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
29 | 4-amino-5,5-dimethyl-2-[5-(3-thienyl)-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
30 | 4-amino-2-[5-(5-fluoropyridin-3-yl)-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
31 | 4-amino-2-[5-(6-fluoropyridin-3-yl)-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
32 | 4-amino-5,5-dimethyl-2-{3-(2,3,6-trifluorobenzyl)-5-[5-(trifluoromethyl)pyridin-3- |
yl]-1H-indazol-1-yl}-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
33 | 4-amino-2-[3-(6-bromo-2,3-difluorobenzyl)-5-chloro-1H-indazol-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
34 | 4-amino-2-[3-(2-cyclopentylethyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
35 | 4-amino-2-(5-fluoro-3-pentyl-1H-indazol-1-yl)-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
36 | 4-amino-2-[5-fluoro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
37 | 4-amino-2-[3-(2-cyclopentylethyl)-5-fluoro-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
38 | 4-amino-2-[3-(2-cyclopentylethyl)-5-fluoro-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
39 | 4-amino-2-[5-fluoro-3-(4,4,4-trifluorobutyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
40 | 4-amino-2-(5-chloro-3-pentyl-1H-indazol-1-yl)-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
41 | 4-amino-2-(3-butyl-5-chloro-1H-indazol-1-yl)-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
42 | 4-amino-2-[5-chloro-3-(4,4,4-trifluorobutyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
43 | 4-amino-2-(5-chloro-3-pent-4-en-1-yl-1H-indazol-1-yl)-5,5-dimethyl-5,7-dihydro- |
6H-pyrrolo[2,3-d]pyrimidin-6-one | |
44 | 4-amino-2-(3-but-3-en-1-yl-5-chloro-1H-indazol-1-yl)-5,5-dimethyl-5,7-dihydro- |
6H-pyrrolo[2,3-d]pyrimidin-6-one | |
45 | 4-amino-2-(5-chloro-3-propyl-1H-indazol-1-yl)-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
46 | ethyl 3-[1-(4-amino-5,5-dimethyl-6-oxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2- |
yl)-5-chloro-1H-indazol-3-yl]propanoate | |
47 | 4-amino-2-[5-chloro-3-(3,3-dimethylbutyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
48 | 4-amino-2-[3-(2,3-difluorobenzyl)-1H-thieno[3,4-c]pyrazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
49 | 4-amino-2-[6-chloro-3-(2,3-difluorobenzyl)-1H-thieno[3,4-c]pyrazol-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
50 | 4-amino-2-[5-chloro-3-(2,3-difluorobenzyl)-1H-thieno[2,3-c]pyrazol-1-yl]-5,5 - |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
51 | 4-amino-2-[3-(2,3-difluorobenzyl)-1H-thieno[3,2-c]pyrazol-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
52 | 4-amino-2-[5-chloro-3-(2,3,6-trifluorobenzyl)-1H-thieno[2,3-c]pyrazol-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
53 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-thieno[3,2-c]pyrazol-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
54 | 4-amino-5,5-dimethyl-2-[5-methyl-3-(2,3,6-trifluorobenzyl)pyrazolo[4,3-c]pyrazo- |
1(5H)-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
55 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-thieno[2,3-c]pyrazol-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
56 | 4-amino-5,5-dimethyl-2-[6-methyl-3-(2,3,6-trifluorobenzyl)pyrazolo[3,4-c]pyrazo- |
1(6H)-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
57 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-pyrazolo[4,3-c]pyridin-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
58 | 4-amino-5,5-dimethyl-2-[7-(2,3,6-trifluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
59 | 4-amino-2-[6-chloro-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
60 | 4-amino-2-[6-fluoro-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
61 | 4-amino-5,5-dimethyl-2-[5-(2,3,6-trifluorobenzyl)imidazo[5,1-b][1,3]thiazol-7-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
62 | 4-amino-5,5-dimethyl-2-[1-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-3-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
63 | 4-amino-2-[3-(2,3-difluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
64 | 4-amino-2-[7-(2,3-difluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
65 | 4-amino-2-[3-(2,3-difluorobenzyl)-6-fluoroimidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
66 | 4-amino-2-[7-(2-fluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
67 | 4-amino-2-[3-(2-fluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
68 | 4-amino-2-[6-fluoro-3-(2-fluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
69 | 4-amino-2-[6-chloro-3-(2-fluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
70 | 4-amino-2-[7-(2,3-difluorobenzyl)-2-methylimidazo[1,5-b]pyridazin-5-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
71 | 4-amino-2-[6-chloro-3-(2,3-difluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
72 | 4-amino-2-(3-benzylimidazo[1,5-a]pyridin-1-yl)-5,5-dimethyl-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
73 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
74 | 4-amino-5,5-dimethyl-2-[6-phenyl-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1- |
yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
75 | 4-amino-2-[6-(2-fluorophenyl)-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]- |
5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
76 | 4-amino-2-[6-(3-fluorophenyl)-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]- |
5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
77 | 4-amino-2-[6-(4-fluorophenyl)-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1- |
yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
78 | 4-amino-2-[6-(3-chlorophenyl)-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]- |
5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
79 | 4-amino-5,5-dimethyl-2-[6-(3-thienyl)-3-(2,3,6-trifluorobenzyl)imidazo[1,5- |
a]pyridin-1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
80 | 4-amino-2-[6-cyclopropyl-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
81 | 4-amino-5,5-dimethyl-2-[7-(3,3,3-trifluoropropyl)imidazo[1,5-b]pyridazin-5-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
82 | 4-amino-5,5-dimethyl-2-[3-(2,4,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
83 | 4-amino-2-[3-(2-chloro-6-fluoro-3-methylbenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
84 | 4-amino-2-[3-(2-cyclopentylethyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
85 | 4-amino-5,5-dimethyl-2-[7-(4,4,4-trifluorobutyl)imidazo[1,5-b]pyridazin-5-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
86 | 4-amino-5,5-dimethyl-2-[3-(4,4,4-trifluorobutyl)imidazo[1,5-a]pyridin-1-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
87 | 4-amino-5,5-dimethyl-2-{3-[2-(2-thienyl)ethyl]imidazo[1,5-a]pyridin-1-yl}-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
88 | 4-amino-2-[3-(2-cyclopropylethyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
89 | 4-amino-5,5-dimethyl-2-(3-pentylimidazo[1,5-a]pyridin-1-yl)-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
90 | 4-amino-5,5-dimethyl-2-(7-pentylimidazo[1,5-b]pyridazin-5-yl)-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
91 | 4-amino-5,5-dimethyl-2-[3-(3-methylbutyl)imidazo[1,5-a]pyridin-1-yl]-5,7-dihydro- |
6H-pyrrolo[2,3-d]pyrimidin-6-one | |
92 | 4-amino-5,5-dimethyl-2-[3-methyl-5-(2,3,6-trifluorobenzyl)imidazo[5,1- |
b][1,3]thiazol-7-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
93 | 4-amino-5,5-dimethyl-2-[2-methyl-5-(2,3,6-trifluorobenzyl)imidazo[5,1- |
b][1,3]thiazol-7-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
94 | 4-amino-2-[5-(2-fluorobenzyl)imidazo[5,1-b][1,3]thiazol-7-yl]-5,5-dimethyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
95 | 4-amino-5,5-dimethyl-2-[1-(3,3,3-trifluoropropyl)-1H-indazol-3-yl]-5,7-dihydro-6H- |
pyrrolo[2,3-d]pyrimidin-6-one | |
96 | 4-amino-2-[5-chloro-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,8- |
dihydropyrido[2,3-d]pyrimidin-7(6H)-one | |
97 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,8- |
dihydropyrido[2,3-d]pyrimidin-7(6H)-one | |
98 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-thieno[3,4-c]pyrazol-1-yl]- |
5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one | |
99 | 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-4,6-dihydro-1H-thieno[3,4- |
c]pyrazol-1-yl]-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one | |
100 | 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5-ethyl-5-methyl- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
101 | 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5-methyl-5-propy- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
102 | 4-amino-2-[5-chloro-3-(3,3-dimethylbutyl)-1H-indazol-1-yl]-5-ethyl-5-methyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
103 | 4-amino-5-ethyl-2-[3-(2-fluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5-methyl-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
104 | 4-amino-5,5-dimethyl-2-[3-(3,3,4,4,4-pentafluorobutyl)-1H-indazol-1-yl]-5,7- |
dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
105 | 4-amino-2-[5-fluoro-3-(3,3,4,4,4-pentafluorobutyl-1H-indazol-1-yl]5,5-dimethyl- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
106 | 4-amino-2-[5-chloro-3-(3,3,4,4,4-pentafluorobutyl)-1H-indazol-1-yl]-5,5-dimethy- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
107 | 4-amino-5,5-dimethyl-2-[3-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[4,3-b]pyridin- |
1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
108 | 4-amino-5,5-dimethyl-2-[3-(3,3,4,4,4-pentafluorobutyl)imidazo[1,5-a]pyridin-1-yl]- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
109 | 4-amino-2-[6-fluoro-3-(3,3,4,4,4-pentafluorobutyl)imidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
110 | 4-amino-2-[6-chloro-3-(3,3,4,4,4-pentafluorobutyl)imidazo[1,5-a]pyridin-1-yl]-5,5- |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
111 | 4-amino-2-[6-chloro-1-(3,3,4,4,4-pentafluorobutyl)-1H-indazol-3-yl]-5,5-dimethy- |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | |
and pharmaceutically acceptable salts thereof.
- 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-2-[5-chloro-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)-1H-thieno[3,4-c]pyrazol-1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-2-[5-chloro-3-(2,3,6-trifluorobenzyl)-1H-thieno[2,3-c]pyrazol-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one
- 4-amino-5,5-dimethyl-2-[7-(2,3,6-trifluorobenzyl)imidazo[1,5-b]pyridazin-5-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-2-[6-chloro-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-2-[6-fluoro-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-2-[3-(2,3-difluorobenzyl)-6-fluoroimidazo[1,5-c]pyridin-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-5,5-dimethyl-2-[3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
- 4-amino-2-[3-(2-cyclopentylethyl)imidazo[1,5-d]pyridin-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one;
and pharmaceutically acceptable salts thereof.
represents an 8- or 9-membered bicyclic heteroaryl ring system, comprised of a 5-membered ring fused to a 5- or 6-membered ring so that the fused rings share two adjacent atoms. In particular, the 8- or 9-membered heteroaryl is composed of a first ring which is a 5-membered ring containing two nitrogens, fused to a second ring that optionally contains one or more heteroatoms (N, O or S). The two nitrogens of the first ring may be fully in the first ring, or one of the two nitrogens may be shared at a fusion point with the second ring. The 8- or 9-membered bicyclic heteroaryl is attached to the pyrmidinyl ring and the —CH2—R2 group of structural Formula I or II via the first ring, and more specifically via each of the atoms in the first ring that are adjacent to each of the two atoms shared by both rings in the bicyclic heteroaryl.
and X1 and X4 are CH. As used herein, * indicates attachment to the pyrmidinyl ring and ** indicates attachment to the —CH2—R2 of structural Formula I or II.
aq, aq. = aqueous | BuLi, n-BuLi = n-butyllithium |
Ar = aryl | DME = 1,2-dimethoxyethane |
Ac = acetate | Bn = benzyl |
Bu = butyl, t-Bu = tert-butyl | BF3•OEt2 = boron trifluoride diethyl etherate |
CHCl3 = chloroform | |
cPr = cyclopropyl | conc, conc. = concentrated |
DCE = dichloroethane | DBU = 1,8-Diazabicyclo[4.3.0]undec-7-ene |
DCM = dichloromethane | dba = dibenzylideneacetone; Pd2dba3 = |
tris(dibenzylidineacetone)dipalladium | |
DIEA = diisopropylethylamine | DMF = N,N-dimethylformamide |
DMAC, DMA = dimethylacetamide | dppf, DPPF = 1,1′-bis(diphenylphosphino)ferrocene |
DMSO = dimethylsulfoxide | DIBAL, DIBAL-H = diisobutylaluminum hydride |
Et = ethyl | EDC = 1-Ethyl-3-(3-dimethylaminopropyl) |
carbodiimidehydrochloride | |
EtOAc = ethyl acetate | EtOH = ethanol |
eq. = equivalent(s) | HPLC = High pressure liquid chromatography |
HOAc - acetic acid | iPA = isopropyl alcohol |
iPr = isopropyl | LAH = Lithium aluminum hydride |
h, hr = hour | IPA, i-PrOH = isopropanol |
LDA = lithium diisopropyl amide | LCMS = liquid chromatography - mass |
spectroscopy | |
Me = methyl | LiHMDS = lithium bis(trimethylsilyl)amide |
MeOH = methanol | min, min. = minute |
Mp = melting point | NaHMDS = sodium bis(trimethylsilyl)amide |
NBS = N-bromo succinmide | NIS = N-iodosuccinimide |
NMP = N-methylpyrrolidinone | NMR = nuclear magnetic resonance |
PDA = photodiode array | Pd/C = palladium on activated carbon |
PdCl2(dppf)2•CH2Cl2 = Dichloro 1,1′- | Pd2(dba)3 = |
bis(diphenylphosphino)ferrocene palladium | Tris(dibenzylideneacetone)dipalladium (0) |
(II) dichloromethane adduct | |
Ph = phenyl | Pr = propyl |
rt = retention time | RT = room temperature |
sat. = saturated | TEA = triethylamine |
THF = tetrahydrofuranTFA = Trifluoroacetic | TLC = thin layer chromatography |
acid | |
prep TLC = preparative thin layer | |
chromatography | |
In one embodiment of the present invention compounds with the structure 40 are prepared as outlined in Scheme 9. Alkylation of nitrile indazole 37 with a base such as cesium carbonate or sodium hydride and an alkyl halide in a solvent such as DMF affords the compound 38. Compound 38 can be converted to compound 40 as described in Scheme 4.
Compounds of the present invention may be prepared using methods familiar to those skilled in the art. One such method is the palladium mediated coupling of a boronic acid or ester and an aryl halide. An example of this method is shown in Scheme 11. The imidazopyridine 45 can be coupled to any suitable boronic acid or boronic ester such as phenyl boronic acid with a catalyst such as dichlorobis[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct to give 46.
-
- Temperature: 50° C.
- Eluent: 10:90 to 98:2 v/v acetonitrile/water+0.05% TFA (or HCOOH) over 3.75 min.
- Flow Rate: 1.0 mL/min, Injection 10 μL
- Detection: PDA, 200-600 nm
- MS: mass range 150-750 amu; positive ion electrospray ionization
-
- Temperature: 50° C.
- Eluent: 10:90 to 98:2 v/v acetonitrile/water+0.05% TFA (or HCOOH) over 1.25 min.
- Flow Rate: 1.5 mL/min, Injection 5 μL
- Detection: PDA, 200-600 nm
- MS: mass range 150-750 amu; positive ion electrospray ionization
-
- Temperature: 50° C.
- Eluent: 10:90 to 98:2 v/v acetonitrile/water+0.05% TFA (or HCOOH) over 3.25 min.
- Flow Rate: 1.5 mL/min, Injection 5 μL
- Detection: PDA, 200-600 nm
- MS: mass range 150-750 amu; positive ion electrospray ionization
-
- Temperature: 50° C.
- Eluent: 10:90 to 100:0 v/v acetonitrile/water+0.05% TFA over 3.75 min.
- Flow Rate: 1.2 mL/min, Injection 10 μL
- Detection: PDA, 200-600 nm
- MS: mass range 150-700 amu; positive ion electrospray ionization
-
- Temperature: 50° C.
- Eluent: 5:95 to 98:2 v/v acetonitrile/water+0.05% TFA over 3.00 min.
- Flow Rate: 2.5 mL/min, Injection 10 μL
- Detection: PDA, 200-600 nm
- MS: mass range 150-700 amu; positive ion electrospray ionization
TABLE 1 |
|
EXAMPLE | R1 | R2 | LC-MS data | Method |
12 | H | 2-F—Ph | 2.19 min (M + H) 403 | LC3 |
13 | Cl | 2-F—Ph | 2.43 min (M + H) 437 | LC3 |
14 | F | 2-F—Ph | 2.28 min (M + H) 421 | LC3 |
15 | Cl | 2,3-di F—Ph | 3.42 min (M + H) 455 | LC1 |
16 | F | 2,3-di F—Ph | 2.36 min (M + H) 439 | LC5 |
17 | H | 2,3-di F—Ph | 3.12 min (M + H) 421 | LC1 |
18 | Ph | 2-F—Ph | 3.55 min (M + H) 479 | LC1 |
19 | F | 2,3,6-tri F—Ph | 2.34 min (M + H) 458 | LC5 |
20 |
|
2,3,6-tri F—Ph | 1.64 min (M + H) 516 | LC5 |
21 |
|
2,3,6-tri F—Ph | 2.12 min (M + H) 520 | LC5 |
22 |
|
2,3,6-tri F—Ph | 1.78 min (M + H) 534 | LC5 |
23 |
|
2,3,6-tri F—Ph | 2.45 min (M + H) 505 | LC5 |
24 |
|
2,3,6-tri F—Ph | 2.61 min (M + H) 535 | LC5 |
25 |
|
2,3,6-tri F—Ph | 2.42 min (M + H) 479 | LC5 |
26 |
|
2,3,6-tri F—Ph | 1.64 min (M + H) 517 | LC5 |
27 | Ph | 2,3,6-tri F—Ph | 2.60 min (M + H) 515 | LC5 |
28 | Cl |
|
3.01 min (M + H) 421 | LC4 |
29 |
|
2,3,6-tri F—Ph | 4.00 min (M + H) 521 | LC4 |
30 |
|
2,3,6-tri F—Ph | 3.64 min (M + H) 534 | LC4 |
31 |
|
2,3,6-tri F—Ph | 3.8 min (M + H) 534 | LC4 |
32 |
|
2,3,6-tri F—Ph | 3.99 min (M + H) 584 | LC4 |
33 | Cl | 2,3-di F, 6-Br—Ph | 4.12 mi. (M + H) 535 | LC4 |
34 | H |
|
1.22 min (M + H) 391 | LC2 |
35 | F | (CH2)3CH3 | 3.84 min (M + H) 383 | LC4 |
36 | F | CH2CF3 | 3.53 min (M + H) 409 | LC4 |
37 | F |
|
1.21 min (M + H) 409 | LC2 |
38 | Cl |
|
1.24 min (M + H) 425 | LC2 |
39 | F | (CH2)2CF3 | 2.06 min (M + H) 423 | LC3 |
40 | Cl | (CH2)3CH3 | 2.09 min (M + H) 399 | LC3 |
41 | Cl | (CH2)2CH3 | 3.95 min (M + H) 385 | LC4 |
42 | Cl | (CH2)2CF3 | 3.81 min (M + H) 439 | LC4 |
43 | Cl | (CH2)2CHCH2 | 3.89 min (M + H) 397 | LC4 |
44 | Cl | CH2CHCH2 | 2.10 min (M + H) 383 | LC3 |
45 | Cl | CH2CH3 | 3.68 min (M + H) 371 | LC4 |
46 | Cl | CH2CO2Et | 3.49 min (M + H) 429 | LC4 |
47 | Cl | CH2C(CH3)3 | 4.29 (M + H) 413 | LC4 |
TABLE 2 |
|
EXAMPLE | X | Z | LC-MS data | Method |
48 |
|
H | 3.47 min (M + H) 427 | LC4 |
49 |
|
H | 3.66 min (M + H) 461 | LC4 |
50 |
|
H | 4.08 min (M + H) 461 | LC4 |
51 |
|
H | 3.63 min (M + H) 427 | LC4 |
52 |
|
F | 3.97 min (M + H) 479 | LC4 |
53 |
|
F | 3.62 min (M + H) 445 | LC4 |
54 |
|
F | 1.89 min (M + H) 443 | LC5 |
55 |
|
F | 3.67 min (M + H) 445 | LC4 |
56 |
|
F | 3.21 min (M + H) 443 | LC4 |
57 |
|
F | 1.46 min (M + H) 440 | LC5 |
TABLE 3 |
|
EXAMPLE | R1 | R2 | X | LC-MS data | Method |
63 | H | 2,3 di F—Ph | CH | 1.05 min.(M + H) 421 | LC2 |
64 | H | 2,3 di F—Ph | N | 1.05 min.(M + H) 422 | LC2 |
65 | F | 2,3 di F—Ph | CH | 1.06 min.(M + H) 439 | LC2 |
66 | H | 2 F—Ph | N | 1.05 min.(M + H) 404 | LC2 |
67 | H | 2 F—Ph | CH | 1.04 min.(M + H) 403 | LC2 |
68 | F | 2 F—Ph | CH | 1.06 min.(M + H) 421 | LC2 |
69 | Cl | 2 F—Ph | CH | 1.08 min.(M + H) 437 | LC2 |
70 | Me | 2,3 di F—Ph | N | 1.62 min.(M + H) 436 | LC3 |
71 | Cl | 2,3 di F—Ph | CH | 1.65 min.(M + H) 455 | LC3 |
72 | H | Ph | CH | 1.04 min.(M + H) 385 | LC2 |
73 | H | 2,3,6-tri F—Ph | CH | 1.49 min.(M + H) 439 | LC3 |
74 | Ph | 2,3,6-tri F—Ph | CH | 1.14 min.(M + H) 515 | LC2 |
75 | 2-F Ph | 2,3,6-tri F—Ph | CH | 1.13 min.(M + H) 533 | LC2 |
76 | 3-F Ph | 2,3,6-tri F—Ph | CH | 1.14 min.(M + H) 533 | LC2 |
77 | 4-F Ph | 2,3,6-tri F—Ph | CH | 1.14 min.(M + H) 533 | LC2 |
78 | 3-Cl Ph | 2,3,6-tri F—Ph | CH | 1.17 min.(M + H) 549 | LC2 |
79 |
|
2,3,6-tri F—Ph | CH | 1.13 min.(M + H) 521 | LC2 |
80 |
|
2,3,6-tri F—Ph | CH | 1.12 min.(M + H) 479 | LC2 |
81 | H | CH2CF3 | N | 0.98 min.(M + H) 392 | LC2 |
82 | H | 2,4,6-tri F—Ph | CH | 1.03 min.(M + H) 439 | LC2 |
83 | H | 2-Cl, 3-Me, 6-F—Ph | CH | 1.07 min.(M + H) 450 | LC2 |
84 | H |
|
CH | 1.1 min.(M + H) 391 | LC2 |
85 | H | CH2CH2CF3 | N | 1.03 min.(M + H) 406 | LC2 |
86 | H | CH2CH2CF3 | CH | 1.02 min.(M + H) 405 | LC2 |
87 | H |
|
CH | 1.38 min.(M + H) 405 | LC4 |
88 | H |
|
CH | 0.98 min.(M + H) 363 | LC2 |
89 | H | (CH2)3CH3 | CH | 0.98 min.(M + H) 365 | LC2 |
90 | H | (CH2)3CH3 | N | 1.35 min.(M + H) 366 | LC4 |
91 | H | CH2CH(CH3)2 | CH | 1.48 min.(M + H) 365 | LC4 |
TABLE 4 |
|
EXAM- | Descrip- | |||
PLE | X | R2 | LC-MS data | tion |
92 |
|
2,3,6-tri F—Ph | 1.75 min. (M + H) 459 | LC3 |
93 |
|
2,3,6-tri F—Ph | 1.52 min. (M + H) 459 | LC3 |
94 |
|
2-F—Ph | 1.38 min. (M + H) 409 | LC3 |
TABLE 5 |
|
EXAMPLE | X | LC-MS data | Method |
97 |
|
3.64 min. (M + H) 453 | LC4 |
98 |
|
3.51 min. (M + H) 459 | LC4 |
99 |
|
3.61 min. (M + H) 461 | LC4 |
TABLE 6 | |||
EXAM- | |||
PLE | Structure | LC-MS data | Method |
102 |
|
4.31 min. (M + H) 427 | LC4 |
103 |
|
0.99 min. (M + H) 417 | LC2 |
TABLE 7 |
|
EXAMPLE | X | LC-MS data | Method |
104 |
|
3.63 min. (M + H) 441 | LC4 |
105 |
|
3.74 min. (M + H) 459 | LC4 |
106 |
|
3.94 min. (M + H) 475 | LC4 |
107 |
|
3.35 min. (M + H) 442 | LC4 |
108 |
|
1.12 min. (M + H) 441 | LC2 |
109 |
|
1.12 min. (M + H) 459 | LC2 |
110 |
|
1.13 min. (M + H) 475 | LC2 |
111 |
|
3.43 min. (M + H) 475 | LC4 |
Example | IUPAC NAME | EC50 |
1 | 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)-1H-indazol-1-yl]-5,5-dimethyl- | 86 nM |
5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | ||
3 | 4-amino-2-[5-chloro-3-(2,3,6-trifluorobenzyl)-1H-indazol-1-yl]-5,5- | 7 nM |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | ||
59 | 4-amino-2-[6-chloro-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]- | 24 nM |
5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | ||
60 | 4-amino-2-[6-fluoro-3-(2,3,6-trifluorobenzyl)imidazo[1,5-a]pyridin-1-yl]- | 31 nM |
5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | ||
111 | 4-amino-2-[6-chloro-1-(3,3,4,4,4-pentafluorobutyl)-1H-indazol-3-yl]-5,5- | 83 nM |
dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | ||
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/127,334 US8741910B2 (en) | 2008-11-25 | 2009-11-16 | Soluble guanylate cyclase activators |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20022108P | 2008-11-25 | 2008-11-25 | |
PCT/US2009/064570 WO2010065275A1 (en) | 2008-11-25 | 2009-11-16 | Soluble guanylate cyclase activators |
US13/127,334 US8741910B2 (en) | 2008-11-25 | 2009-11-16 | Soluble guanylate cyclase activators |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110218202A1 US20110218202A1 (en) | 2011-09-08 |
US8741910B2 true US8741910B2 (en) | 2014-06-03 |
Family
ID=42233549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/127,334 Active 2030-09-20 US8741910B2 (en) | 2008-11-25 | 2009-11-16 | Soluble guanylate cyclase activators |
Country Status (6)
Country | Link |
---|---|
US (1) | US8741910B2 (en) |
EP (1) | EP2373317B1 (en) |
JP (1) | JP5501369B2 (en) |
AU (1) | AU2009322836B2 (en) |
CA (1) | CA2743864A1 (en) |
WO (1) | WO2010065275A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9505786B2 (en) | 2012-01-11 | 2016-11-29 | Bayer Pharma Aktiengesellschaft | Substituted annulated triazines and use thereof |
US9605008B2 (en) | 2013-07-10 | 2017-03-28 | Bayer Pharma Aktiengesellschaft | Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof |
US9611278B2 (en) | 2013-12-11 | 2017-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
US9822130B2 (en) | 2014-11-21 | 2017-11-21 | Merck Sharp & Dohme Corp. | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10030027B2 (en) | 2015-12-22 | 2018-07-24 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
US10780092B2 (en) | 2016-05-16 | 2020-09-22 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236316B2 (en) | 2007-11-21 | 2012-08-07 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
EP2373691B1 (en) | 2008-12-18 | 2019-01-23 | Oregon Health&Science University | Anti-fxi antibodies and methods of use |
EP2549875B1 (en) * | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
NZ603799A (en) | 2010-05-26 | 2014-10-31 | Bayer Ip Gmbh | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc). |
WO2011149921A1 (en) | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP2585055A1 (en) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
DE102011007891A1 (en) | 2011-04-21 | 2012-10-25 | Bayer Pharma Aktiengesellschaft | New ring-fused 4-aminopyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease and renal insufficiency |
CN106977530A (en) | 2010-07-09 | 2017-07-25 | 拜耳知识产权有限责任公司 | Ring fusion pyrimidine and triazine and its be used for treat and/or prevention of cardiovascular disease purposes |
DE102010031148A1 (en) | 2010-07-09 | 2012-01-12 | Bayer Schering Pharma Ag | New 1-(2-fluoro-benzyl)-1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease |
DE102010031149A1 (en) | 2010-07-09 | 2012-01-12 | Bayer Schering Pharma Aktiengesellschaft | New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease |
DE102011003315A1 (en) | 2011-01-28 | 2012-08-02 | Bayer Schering Pharma Aktiengesellschaft | New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful for treating and/or preventing e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease, and fibrotic disorder |
JP5940062B2 (en) * | 2010-07-09 | 2016-06-29 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Ring-fused 4-aminopyrimidine and its use as a stimulant of soluble guanylate cyclase |
DE102010040233A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic aza heterocycles and their use |
EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102012200356A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | New substituted imidazopyrid(az)ine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency |
DE102011075399A1 (en) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | New substituted imidazopyrid(az)ine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency |
WO2012122340A1 (en) | 2011-03-10 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
CA2833698A1 (en) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
DE102011007890A1 (en) | 2011-04-21 | 2012-10-25 | Bayer Pharma Aktiengesellschaft | New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency |
DE102012200357A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency |
DE102011075398A1 (en) | 2011-05-06 | 2012-11-08 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridazines and their use |
ES2592267T3 (en) * | 2011-05-06 | 2016-11-29 | Bayer Intellectual Property Gmbh | Imidazopyridines and substituted imidazopyridazines and their use |
DE102012200354A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | New heteroaryl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency |
DE102011078715A1 (en) | 2011-07-06 | 2013-01-10 | Bayer Pharma AG | New substituted pyrazolo-pyridine derivatives useful for treating and/or prophylaxis of e.g. congestive heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular diseases, renal failure, and fibrotic diseases |
AU2012280246A1 (en) | 2011-07-06 | 2014-01-23 | Bayer Intellectual Property Gmbh | Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators |
US8815857B2 (en) | 2011-08-12 | 2014-08-26 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
DE102011082041A1 (en) | 2011-09-02 | 2013-03-07 | Bayer Pharma AG | New substituted fused pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases |
EP2751106B1 (en) * | 2011-09-02 | 2017-10-18 | Bayer Intellectual Property GmbH | Substituted annellated pyrimidine and the use thereof |
DE102012200351A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Pharma Aktiengesellschaft | New substituted annellated pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases |
EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
DE102012200352A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted, fused imidazoles and pyrazoles and their use |
DE102012200360A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted triazines and their use |
JP6140738B2 (en) * | 2012-03-06 | 2017-05-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Substituted azabicycles and uses thereof |
LT2847228T (en) | 2012-05-10 | 2018-11-12 | Bayer Pharma Aktiengesellschaft | ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XI AND/OR ITS ACTIVATED FORM FACTOR XIa AND USES THEREOF |
GEP20176631B (en) | 2012-09-07 | 2017-02-27 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
EP2961754B1 (en) | 2013-03-01 | 2016-11-16 | Bayer Pharma Aktiengesellschaft | Benzyl-substituted pyrazolopyridines and use thereof |
SG11201505974VA (en) | 2013-03-01 | 2015-09-29 | Bayer Pharma AG | Trifluormethyl-substituted ring-fused pyrimidines and use thereof |
RS63108B1 (en) | 2013-03-15 | 2022-04-29 | Cyclerion Therapeutics Inc | Sgc stimulators |
ES2625744T3 (en) | 2013-06-04 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Imidazo [1,2-a] pyridines substituted with 3-aryl and their use |
EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
US9868722B2 (en) | 2013-12-10 | 2018-01-16 | Cleave Biosciences, Inc. | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex |
CN106304835A (en) | 2013-12-11 | 2017-01-04 | 铁木医药有限公司 | Sgc stimulant |
US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
BR112016016421B1 (en) | 2014-01-20 | 2022-10-18 | Cleave Biosciences, Inc | FUSED PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE |
US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
TWI711615B (en) | 2014-07-22 | 2020-12-01 | 德商百靈佳殷格翰國際股份有限公司 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
CN107108658A (en) | 2014-08-29 | 2017-08-29 | 拜耳医药股份有限公司 | Substituted cyclic pyrimidin and application thereof |
CA2959199A1 (en) | 2014-08-29 | 2016-03-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted annulated pyrimidines and use thereof |
JP6832846B2 (en) * | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドPlexxikon Inc. | Heterocyclic compounds and their uses |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
JP6624616B2 (en) | 2014-09-17 | 2019-12-25 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC stimulant |
CA2969268A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-a]pyridines and their use |
EP3291811B1 (en) | 2015-05-06 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
SI3325013T2 (en) | 2015-07-23 | 2023-11-30 | Bayer Pharma Aktiengesellschaft | Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof |
EP3389655A2 (en) | 2015-12-14 | 2018-10-24 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
WO2017121692A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituted sulfamides and use of same |
WO2017121700A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase |
WO2017121693A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituted thiazole and thiadiazole amides, and use thereof |
CA3029374A1 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Phosphorus prodrugs of sgc stimulators |
JP2019524710A (en) | 2016-07-07 | 2019-09-05 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Solid form of SGC stimulant |
SG11201901729YA (en) | 2016-09-02 | 2019-03-28 | Ironwood Pharmaceuticals Inc | Fused bicyclic sgc stimulators |
CN109890379A (en) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | Combination product comprising sGC activator and mineralocorticoid receptor antagonists |
EP3525779A1 (en) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Combination containing sgc stimulators and mineralocorticoid receptor antagonists |
CA3042713A1 (en) | 2016-11-08 | 2018-05-17 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
MX2019005342A (en) | 2016-11-08 | 2019-10-02 | Cyclerion Therapeutics Inc | Treatment of cns diseases with sgc stimulators. |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2018153899A1 (en) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Use of activators and stimulators of sgc comprising a beta2 subunit |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
JP7337067B2 (en) | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC stimulant |
MX2020009183A (en) | 2018-03-07 | 2020-10-08 | Cyclerion Therapeutics Inc | Crystalline forms of an sgc stimulator. |
CN112055584A (en) | 2018-04-30 | 2020-12-08 | 拜耳公司 | Use of sGC activators and sGC stimulators for the treatment of cognitive disorders |
SG11202011018PA (en) | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
MX2021000363A (en) | 2018-07-11 | 2021-04-29 | Cyclerion Therapeutics Inc | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS. |
BR112021009958A2 (en) | 2018-11-28 | 2021-08-17 | Topadur Pharma Ag | dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses |
CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2021195403A1 (en) | 2020-03-26 | 2021-09-30 | Cyclerion Therapeutics, Inc. | Deuterated sgc stimulators |
WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
WO2022225903A1 (en) | 2021-04-20 | 2022-10-27 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
TW202308634A (en) | 2021-04-20 | 2023-03-01 | 美商賽克瑞恩醫療公司 | Treatment of cns diseases with sgc stimulators |
WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665732A (en) | 1993-03-18 | 1997-09-09 | Merck, Sharp & Dohme Ltd. | Indazole derivatives |
DE19744027A1 (en) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | New pyrazolo(3,4-b)pyridine derivatives useful as cGMP agonists |
EP0908456A1 (en) | 1997-10-06 | 1999-04-14 | Hoechst Marion Roussel Deutschland GmbH | Pyrazole derivatives, their preparation and their use in drugs |
US6166027A (en) | 1996-10-14 | 2000-12-26 | Bayer Aktiengesellschaft | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases |
WO2001083490A1 (en) | 2000-04-28 | 2001-11-08 | Bayer Aktiengesellschaft | Substituted pyrazole derivative |
WO2002042300A1 (en) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Novel carbamate-substituted pyrazolopyridine derivatives |
WO2002042299A1 (en) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
WO2002059083A2 (en) | 2000-10-23 | 2002-08-01 | Smithkline Beecham Corporation | Novel compounds |
US6613772B1 (en) | 1997-12-18 | 2003-09-02 | Aventis Pharma Deutschland Gmbh | Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments |
WO2003095451A1 (en) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
US6693102B2 (en) | 2000-11-22 | 2004-02-17 | Bayer Aktiengesellschaft | Pyridine-substituted pyrazolopyridine derivatives |
US20040048866A1 (en) | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
US20040053915A1 (en) | 2000-11-02 | 2004-03-18 | Volker Geiss | Use of stimulators of soluble guanylate cyclase for treating osteoporosis |
US6743798B1 (en) | 1998-07-29 | 2004-06-01 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
US6844347B1 (en) | 1998-08-13 | 2005-01-18 | Aventis Pharma Deutschland Gmbh | Substituted 4-amino-2aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
EP1390365B1 (en) | 2001-05-11 | 2005-02-02 | Bayer HealthCare AG | Novel sulfonate substituted pyrazol pyridine dervivatives |
WO2005046725A1 (en) | 2003-11-06 | 2005-05-26 | Bayer Healthcare Ag | Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance |
US20050222170A1 (en) | 2002-05-17 | 2005-10-06 | Stefan Weigand | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators |
US6958344B2 (en) | 2000-02-11 | 2005-10-25 | Astrazeneca Ab | Pyrimidine compounds and their use as modulators of chemokine receptor activity |
US20060014915A1 (en) | 2003-08-14 | 2006-01-19 | Dongchan Ahn | Silicones having improved surface properties and curable silicone compositions for preparing the silicones |
US7045526B2 (en) | 1999-02-05 | 2006-05-16 | Sanofi-Aventis Deutschland Gmbh | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them |
US20060106041A1 (en) | 2004-11-16 | 2006-05-18 | Industrial Technology Research Institute | Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents |
US7115599B2 (en) | 2000-11-22 | 2006-10-03 | Bayer Aktiengesellschaft | Sulfonamide-substituted pyrazolopyridine compounds |
US7138402B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | Pyrrolopyrimidines and related analogs as HSP90-inhibitors |
WO2007003435A2 (en) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Use of activators of the soluble guanylate cyclase for promoting the healing of wounds |
WO2007009607A1 (en) | 2005-07-18 | 2007-01-25 | Bayer Healthcare Ag | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
WO2007124854A1 (en) | 2006-04-27 | 2007-11-08 | Bayer Healthcare Ag | Heterocyclic substituted, anellated pyrazole derivative and its uses |
US20080027092A1 (en) | 2003-11-26 | 2008-01-31 | Roger Victor Bonnert | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders |
WO2008031513A1 (en) | 2006-09-15 | 2008-03-20 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivates as stimulators of guanylate cyclase for cardiovascular disorders |
WO2008061657A1 (en) | 2006-11-21 | 2008-05-29 | Bayer Schering Pharma Aktiengesellschaft | Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase |
US20080188666A1 (en) | 2006-11-08 | 2008-08-07 | Markus Berger | Linear phenyl-substituted indazoles and indoles, a process for their production and their use as anti-inflammatory agents |
US7666867B2 (en) | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
US7674825B2 (en) | 1999-09-13 | 2010-03-09 | Bayer Aktiengesellschaft | Dicarboxylic acid derivatives with pharmaceutical properties |
WO2011019581A1 (en) | 2009-08-13 | 2011-02-17 | Commscope, Inc. Of North Carolina | Fiber management component |
US7985876B2 (en) | 2007-03-29 | 2011-07-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted dibenzoic acid derivatives and use thereof |
WO2011149921A1 (en) | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US20120029002A1 (en) | 2009-01-09 | 2012-02-02 | Bayer Schering Pharma Aktiengesellschaft | Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases |
US8183271B2 (en) | 2005-10-21 | 2012-05-22 | Bayer Intellectual Property Gmbh | Tetrazole derivatives and their use for the treatment of cardiovascular diseases |
US8217063B2 (en) | 2007-03-29 | 2012-07-10 | Bayer Intellectual Property Gmbh | Lactam-substituted dicarboxylic acids and use thereof |
US8222262B2 (en) | 2006-10-03 | 2012-07-17 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB876526A (en) | 1957-12-24 | 1961-09-06 | Geigy Ag J R | Process for the production of new aminobenzoic acid derivatives and their use in pest control |
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (en) | 1988-12-09 | 1990-06-13 | Hoechst Ag | ENZYME-INFRINGING DERIVATIVES OF DIPEPTIDES, METHOD FOR THE PRODUCTION THEREOF, METHODS CONTAINING THEM AND THEIR USE |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
-
2009
- 2009-11-16 WO PCT/US2009/064570 patent/WO2010065275A1/en active Application Filing
- 2009-11-16 AU AU2009322836A patent/AU2009322836B2/en not_active Ceased
- 2009-11-16 EP EP09830834.9A patent/EP2373317B1/en active Active
- 2009-11-16 US US13/127,334 patent/US8741910B2/en active Active
- 2009-11-16 JP JP2011537535A patent/JP5501369B2/en not_active Expired - Fee Related
- 2009-11-16 CA CA2743864A patent/CA2743864A1/en not_active Abandoned
Patent Citations (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665732A (en) | 1993-03-18 | 1997-09-09 | Merck, Sharp & Dohme Ltd. | Indazole derivatives |
US6166027A (en) | 1996-10-14 | 2000-12-26 | Bayer Aktiengesellschaft | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases |
DE19744027A1 (en) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | New pyrazolo(3,4-b)pyridine derivatives useful as cGMP agonists |
EP0908456A1 (en) | 1997-10-06 | 1999-04-14 | Hoechst Marion Roussel Deutschland GmbH | Pyrazole derivatives, their preparation and their use in drugs |
US6162819A (en) | 1997-10-06 | 2000-12-19 | Aventis Pharma Deutschland Gmbh | Pyrazole derivatives, their preparation and their use in pharmaceuticals |
US6613772B1 (en) | 1997-12-18 | 2003-09-02 | Aventis Pharma Deutschland Gmbh | Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments |
US6743798B1 (en) | 1998-07-29 | 2004-06-01 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
US6844347B1 (en) | 1998-08-13 | 2005-01-18 | Aventis Pharma Deutschland Gmbh | Substituted 4-amino-2aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
US7045526B2 (en) | 1999-02-05 | 2006-05-16 | Sanofi-Aventis Deutschland Gmbh | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical preparations comprising them |
US7674825B2 (en) | 1999-09-13 | 2010-03-09 | Bayer Aktiengesellschaft | Dicarboxylic acid derivatives with pharmaceutical properties |
US6958344B2 (en) | 2000-02-11 | 2005-10-25 | Astrazeneca Ab | Pyrimidine compounds and their use as modulators of chemokine receptor activity |
WO2001083490A1 (en) | 2000-04-28 | 2001-11-08 | Bayer Aktiengesellschaft | Substituted pyrazole derivative |
WO2002059083A2 (en) | 2000-10-23 | 2002-08-01 | Smithkline Beecham Corporation | Novel compounds |
US20040053915A1 (en) | 2000-11-02 | 2004-03-18 | Volker Geiss | Use of stimulators of soluble guanylate cyclase for treating osteoporosis |
WO2002042300A1 (en) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Novel carbamate-substituted pyrazolopyridine derivatives |
EP1339717B1 (en) | 2000-11-22 | 2005-02-09 | Bayer HealthCare AG | Novel carbamate-substituted pyrazolopyridine derivatives |
US6693102B2 (en) | 2000-11-22 | 2004-02-17 | Bayer Aktiengesellschaft | Pyridine-substituted pyrazolopyridine derivatives |
WO2002042299A1 (en) | 2000-11-22 | 2002-05-30 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
US7115599B2 (en) | 2000-11-22 | 2006-10-03 | Bayer Aktiengesellschaft | Sulfonamide-substituted pyrazolopyridine compounds |
EP1390365B1 (en) | 2001-05-11 | 2005-02-02 | Bayer HealthCare AG | Novel sulfonate substituted pyrazol pyridine dervivatives |
US7666867B2 (en) | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
US20040048866A1 (en) | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
WO2003095451A1 (en) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
US20060052397A1 (en) | 2002-05-08 | 2006-03-09 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
US7173037B2 (en) | 2002-05-08 | 2007-02-06 | Bayer Healthcare Ag | Carbamate-substituted pyrazolopyridines |
US20050222170A1 (en) | 2002-05-17 | 2005-10-06 | Stefan Weigand | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators |
EP1509228B1 (en) | 2002-05-17 | 2005-12-14 | Bayer HealthCare AG | Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators |
US20060014915A1 (en) | 2003-08-14 | 2006-01-19 | Dongchan Ahn | Silicones having improved surface properties and curable silicone compositions for preparing the silicones |
US7138402B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | Pyrrolopyrimidines and related analogs as HSP90-inhibitors |
WO2005046725A1 (en) | 2003-11-06 | 2005-05-26 | Bayer Healthcare Ag | Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance |
US20080027092A1 (en) | 2003-11-26 | 2008-01-31 | Roger Victor Bonnert | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders |
US20060106041A1 (en) | 2004-11-16 | 2006-05-18 | Industrial Technology Research Institute | Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents |
WO2007003435A2 (en) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Use of activators of the soluble guanylate cyclase for promoting the healing of wounds |
WO2007009607A1 (en) | 2005-07-18 | 2007-01-25 | Bayer Healthcare Ag | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
US8183271B2 (en) | 2005-10-21 | 2012-05-22 | Bayer Intellectual Property Gmbh | Tetrazole derivatives and their use for the treatment of cardiovascular diseases |
WO2007124854A1 (en) | 2006-04-27 | 2007-11-08 | Bayer Healthcare Ag | Heterocyclic substituted, anellated pyrazole derivative and its uses |
WO2008031513A1 (en) | 2006-09-15 | 2008-03-20 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivates as stimulators of guanylate cyclase for cardiovascular disorders |
US8309551B2 (en) | 2006-09-15 | 2012-11-13 | Bayer Intellectual Property Gmbh | Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders |
US8222262B2 (en) | 2006-10-03 | 2012-07-17 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
US20080188666A1 (en) | 2006-11-08 | 2008-08-07 | Markus Berger | Linear phenyl-substituted indazoles and indoles, a process for their production and their use as anti-inflammatory agents |
WO2008061657A1 (en) | 2006-11-21 | 2008-05-29 | Bayer Schering Pharma Aktiengesellschaft | Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase |
US8114400B2 (en) | 2006-11-21 | 2012-02-14 | Bayer Pharma Aktiengesellschaft | Aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase |
US8217063B2 (en) | 2007-03-29 | 2012-07-10 | Bayer Intellectual Property Gmbh | Lactam-substituted dicarboxylic acids and use thereof |
US7985876B2 (en) | 2007-03-29 | 2011-07-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted dibenzoic acid derivatives and use thereof |
US20120029002A1 (en) | 2009-01-09 | 2012-02-02 | Bayer Schering Pharma Aktiengesellschaft | Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases |
WO2011019581A1 (en) | 2009-08-13 | 2011-02-17 | Commscope, Inc. Of North Carolina | Fiber management component |
WO2011149921A1 (en) | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
Non-Patent Citations (16)
Title |
---|
Bayer AG Investor Conference Call (edited transcript), (2012) pp. 1-19. |
Boerrigter et al., Handbook of Experimental Pharmacology, (2009), vol. 191, "Modulation of cGMP in Heart Failure: A New Therapeutic Paradigm", pp. 485-506. |
English translation of DE19,744,027 abstract, Aug. 4, 1999. |
Frey et al., BMC Pharmacology, (2007) "BAY 58-2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers" pp. 1-2. |
Ghofrani et al., Eur. Respiratory Rev. (2009), vol. 18, "Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy" pp. 35-41. |
Hering, K.W., et. al., "The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase"; Bioorg. Med. Chem. Lett, 2006, vol. 16, pp. 618-621. |
Hoenicka, M.J., "Purified soluble guanylyl cyclase expressed in baculovirus/sf9 system: stimulation by YC-1, nitric oxide and carbon monoxide"; J. Mol. Med., 1999, vol. 77, pp. 14-23. |
International Preliminary Report on Patentability PCT/US2009/064570 dated May 31, 2011. |
International Search Report of PCT/US2009/064570 dated Jan. 27, 2010. |
Mulsch, a., et. al., "Effect of YC-1, an NO-independent, super-oxide sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators", British Journal of Pharmacology, 1997, vol. 120, pp. 681-689. |
Stasch, et. al., "Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41/8543: in vitro studies", British Journal of Pharmacology, vol. 135, 2002, pp. 333-343. |
Stasch, J. P., et. al., "NO-independent regulatory site on soluble guanylate cyclase"; Nature, vol. 410, 2001, pp. 212-215. |
Stasch, J.P., et. al., "Cardiovascular actions of a novel No-independent guanylyl cyclase stimulator, BAY 41/8543: in vivo studies", British Journal of Pharmacology, vol. 135, 2002, pp. 344-355. |
Straub, A., et. al., "Metabolites of Orally Active No-independent Pyrazolopyridine Stimulators of Soluble Guanylate Cyclase", Bioorg. Med. Chem., vol. 10, 2002, pp. 1711-1717. |
Straub, A., et. al., "NO Independent stimulators of Soluble Guanylate Cyclase"; Bioorg. Med.Chem.Lett, vol. 11, 2001, pp. 781-784. |
Supplementary European Search Report of EP 09830834 dated Feb. 8, 2013. |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9505786B2 (en) | 2012-01-11 | 2016-11-29 | Bayer Pharma Aktiengesellschaft | Substituted annulated triazines and use thereof |
US9605008B2 (en) | 2013-07-10 | 2017-03-28 | Bayer Pharma Aktiengesellschaft | Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof |
US9611278B2 (en) | 2013-12-11 | 2017-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
US9822130B2 (en) | 2014-11-21 | 2017-11-21 | Merck Sharp & Dohme Corp. | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10030027B2 (en) | 2015-12-22 | 2018-07-24 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
US10428076B2 (en) | 2015-12-22 | 2019-10-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
US10780092B2 (en) | 2016-05-16 | 2020-09-22 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
Also Published As
Publication number | Publication date |
---|---|
CA2743864A1 (en) | 2010-06-10 |
JP5501369B2 (en) | 2014-05-21 |
US20110218202A1 (en) | 2011-09-08 |
WO2010065275A1 (en) | 2010-06-10 |
AU2009322836B2 (en) | 2013-04-04 |
EP2373317B1 (en) | 2016-12-14 |
EP2373317A4 (en) | 2013-03-20 |
JP2012509877A (en) | 2012-04-26 |
AU2009322836A1 (en) | 2011-06-23 |
EP2373317A1 (en) | 2011-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8741910B2 (en) | Soluble guanylate cyclase activators | |
US9365574B2 (en) | Soluble guanylate cyclase activators | |
US9783552B2 (en) | Soluble guanylate cyclase activators | |
US9284301B2 (en) | Soluble guanylate cyclase activators | |
US9611278B2 (en) | Soluble guanylate cyclase activators | |
US9796733B2 (en) | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators | |
JP2012509877A5 (en) | ||
US10245264B2 (en) | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators | |
AU2020383423A1 (en) | Allosteric EGFR inhibitors and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROCKUNIER, LINDA L.;PARMEE, EMMA R.;ROSAUER, KEITH;AND OTHERS;SIGNING DATES FROM 20091111 TO 20091113;REEL/FRAME:026281/0841 |
|
AS | Assignment |
Owner name: SCHERING CORPORATION, NEW JERSEY Free format text: MERGER;ASSIGNOR:MERCK SHARP & DOHME CORP.;REEL/FRAME:028850/0515 Effective date: 20120426 |
|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING CORPORATION;REEL/FRAME:028866/0511 Effective date: 20120502 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: MERCK SHARP & DOHME LLC, NEW JERSEY Free format text: MERGER;ASSIGNOR:MERCK SHARP & DOHME CORP.;REEL/FRAME:061102/0145 Effective date: 20220407 |